**UNITED
      STATES**


**SECURITIES
      AND EXCHANGE COMMISSION**


Washington,
      D.C. 20549








**FORM
      10-K**





x ANNUAL
      REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
      1934




For
      the
      Fiscal Year Ended **December
      31, 2006**








**INTEGRATIVE
      HEALTH TECHNOLOGIES, INC.**






**Delaware**
              
              **11-3504866**(State
                  or other jurisdiction of incorporation or organization)
              
              (I.R.S.
                  Employer
                Identification
                  Number)





**4940
      Broadway Suite 201 San Antonio, TX 78209**


(Address
      of principal executive offices) (Zip Code)





**(210)
      824.4200**


(Registrant's
      telephone number, including area code)





Issued
      pursuant to Section 12(b) of the Act:


**None**





Securities
      registered pursuant to Section 12(g) of the Act:


**Common
      Stock, par value $0.00001 per share**













Indicate
      by check mark if the registrant is a well-known seasoned issuer, as defined
      in
      Rule 405 of the Securities Act.


** ̈** **Yes** x **No**





Indicate
      by check mark if the registrant is not required to file reports pursuant to
      Section 13 or Section 15(d) of the Act.


** ̈** **Yes** x **No**





Indicate
      by check mark whether the registrant (1) has filed all reports required to
      be
      filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
      the
      preceding 12 months (or for such shorter period that the registrant was required
      to file such reports), and (2) has been subject to such filing requirements
      for
      the past 90 days:


x **Yes** ** ̈** **No**





Indicate
      by check mark if disclosure of delinquent filers pursuant to Item 405 of
      Regulation S-K is not contained herein, and will not be contained, to the best
      of registrant’s knowledge, in definitive proxy or information statements
      incorporated by reference in Part III of this Form 10-K or any amendment to
      this
      Form 10-K. ****


**x**





Indicate
      by check mark whether the registrant is a large accelerated filer, an
      accelerated filer, or a non-accelerated filer. See definition of "accelerated
      filer and large accelerated filer" in Rule 12b-2 of the Exchange
      Act.


oLarge
      accelerated filer


oAccelerated
      filer


xNon-accelerated
      filer





Indicate
      by check mark whether the registrant is a shell company (defined in Rule 12b-2
      of the Act).


**o** **Yes** **x** **No**





The
      number of shares outstanding of Integrative Health Technologies, Inc.’s common
      stock on April 16, 2007 was 40,642,597.






-
          2
          -


**TABLE
      OF CONTENTS**


**Item
        1.** Caveats
        Regarding Forward Looking Statements
 **Item
        2.** Formation of the Business and Historical Summary of Senticore, Inc.
        (SNIO)
 **Item
        3.** Current
        Description of Integrative Health Technology, Inc.’s (IHTI) Business (With
        subsequent events)
 A.
            Company
                Mission B.
            Revenue
                Sources C.
            Historical
                Summary of IHTI’s Activities (includes significant events subsequent to
                the end of the quarter) **Item
        4.** Market
        for Registrant’s Common Stock
 **Item
        5.** Selected
        Financial Data: Graphic Depictions of:
 *A.
        Number of Issued and Outstanding Shares (by quarter)*
 *B.
        Net Profit/(Loss) (by quarters and cumulative)*
 *C.
        Net Assets per quarter*
 *D.
        Shareholder’s Equity*
 *E.
        Equity per Share*
 **Item
        6** .
        Management's Discussion and Analysis of Financial Condition and Results of
        Operations
 Operating
        Changes
 Previous
        Investment Strategy
 Changes
        in Investment Strategy and Operating Policies and Actions Taken by Current
        Management
 Activities
        of Portfolio Companies
 Health
        and Medical Research, Inc.
 HealthTech
        Development, LLC
 HealthTech
        Products, LLCBoard of Directors passed a resolution recommending the Company
        withdraw its BDC status
 Board
        of
        Directors passed a resolution recommending a reverse split of the Company’s
        stock
 Board
        of
        Directors passed a resolution recommending conversion ratio of preferred
        stock
        from 400 to 1 to 2 to 1
 Company
        receives an independent audit of its portfolio company, IHT-IL
 IHT-IL’s
        Scientific Advisory Board agreed to serve as IHHT’s Scientific Advisory
        Board
 Company
        acquires three wholly owned portfolio companies in the healthcare
        industry
 Liabilities
        reduced through exchanging or selling of shares in non-core
        investments
 Issuance
        of new shares suspended as of June 3, 2006
 Number
        of
        outstanding shares reduced by recapturing and exchanging shares in non-core
        investments
 Plan
        to
        liquidate all non-core investments adopted
 Operating
        expenses met through managerial fees received from portfolio
        companies
 **Item
        7** .
        Financial Statements
 **Item
        8.** Notes to
        Financial Statements
 *A.*
            *Development
                Stage* *B.*
            *Basis
                of Presentation* *C.*
            *Management’s
                Use of Estimates* *D.*
            *Stock-Based
                Compensation* *E.*
            *Valuation
                of Long-Lived and Intangible Assets* *F.*
            *Earnings/(Loss)
                Per Share* G.
            Income
                taxes H.
            Related
                party transactions I.
            Significant
                events subsequent to the end of the quarter. (All significant events
                are
                reported above in Item 3-C.) **Item
        9.** Subsequent
        Events (Incorporated into Items 2 and 3)
 **Item
        10.** Quantitative and Qualitative Disclosures about Market Risk
 *Reverse
        stock split*
 *Impending
        Issuance of 40 million shares after reverse split is
        consummated*
 *Uncertainties
        of reorganization and restructuring*
 *Uncertain
        effects of de-election of Company’s BDC status*
 *Uncertainties
        of resolution of unresolved issues inherited from previous
        management*
 *General
        nature of unresolved issues*
 **Item
        11** .
        Controls and Procedures
 *Quarterly
        evaluation controls*
 *CEO/CFO
        Certifications*
 *Disclosure
        controls and internal controls*
 *Limitations
        on the effectiveness of controls*
 *Scope
        of the evaluation*
 *Conclusions*
 **Item
        12.** Directors
        and Officers of the Registrant
 **Item
        13.** Security
        Ownership of Certain Beneficial Owners and Management Owners of 5% or more
        of
        the common stock (as converted after the reverse split) of Integrative Health
        Technologies, Inc.
 **Item
        14.** Unregistered Sales of Equity Securities and Use of Proceeds
 **Item
        15.** Defaults
        upon Senior Securities
 **Item
        16.** Submission of Matters to a Vote of Securities Holders
 **Item
        17** .
        Other
        Information
 **Item
        18** .
        Exhibits


-
            3
            -




**Item
      1. Caveats Regarding Forward Looking Statements**





The
      matters discussed in this section and in certain other sections of this Form
      10-K contain forward-looking statements within the meaning of Section 21D of
      the
      Securities Exchange Act of 1934, as amended, and Section 27A of the Securities
      Act of 1933, as amended, that involve risks and uncertainties. All statements
      other than statements of historical information provided herein may be deemed
      to
      be forward-looking statements. Without limiting the foregoing, the words "may",
      "will", "could", "should", "intends", "thinks", "believes", "anticipates",
      "estimates", "plans", "expects", or the negative of such terms and similar
      expressions are intended to identify assumptions and uncertainties which could
      cause actual results to differ materially from those expressed in them. Any
      forward-looking statements are qualified in their entirety by reference to
      the
      factors discussed throughout this report. The following cautionary statements
      identify important factors that could cause Integrative Health Technologies,
      Inc. ("IHTI," "we" or "Company") actual results to differ materially from those
      projected in the forward-looking statements made in this Report. Among the
      key
      factors that have a direct bearing on IHTI’s results of operations
      include:





·
            General
                economic and business conditions; changes in political, social and
                economic conditions;


·
            Previous
                management’s widespread failure to comply with government
                regulations;


·
            Absence
                of adequate corporate books and records and improperly issued shares
                from
                2003 through May 2006


·
            Success
                of operating initiatives; changes in business strategy or development
                plans; management of growth;


·
            Changes
                in marketing and technology; availability, terms and deployment of
                capital;


·
            Legal,
                administrative and accounting expenses; existence or absence of adverse
                publicity;


·
            Short-term
                over reliance on senior management; business abilities and judgment
                of
                personnel;


·
            Availability
                of qualified personnel


·
            Development
                risks; risks relating to the availability of financing, and other
                factors
                referenced in this Report.





Because
      the risks factors referred to above could cause actual results or outcomes
      to
      differ materially from those expressed in any forward-looking statements made
      by
      IHTI, you should not place undue reliance on any such forward-looking
      statements. Other factors may be described from time to time in IHTI's other
      filings with the Securities and Exchange Commission, news releases and other
      communications. Further, any forward-looking statement speaks only as of the
      date on which it is made and IHTI undertakes no obligation to update any
      forward-looking statement or statements to reflect events or circumstances
      after
      the date on which such statement is made or to reflect the occurrence of
      unanticipated events. New factors emerge from time to time, and it is not
      possible for IHTI to predict which will arise. In addition, IHTI cannot assess
      the impact of each factor on IHTI's business or the extent to which any factor,
      or combination of factors, may cause actual results to differ materially from
      those contained in any forward-looking statements. Subsequent written and oral
      forward-looking statements attributable to IHTI or persons acting on its behalf
      are expressly qualified in their entirety by the cautionary statements set
      forth
      above and contained elsewhere in this Annual Report on Form 10-K.





IHTI
      has
      been and is currently subject to the informational requirements of the
      Securities Exchange Act of 1934 and the Investment Company Act of 1940 as
      amended. In accordance with those requirements, we file reports and other
      information with the Securities and Exchange Commission. Such reports and other
      information can be inspected and copied at the public reference facilities
      maintained by the SEC. Please call the SEC at 1-800-SEC-0330 for more
      information on the operation of its public reference rooms. The SEC also
      maintains a Web site that contains reports, proxy and information statements
      and
      other materials that are filed through the SEC's Electronic Data Gathering,
      Analysis, and Retrieval (EDGAR) system. All of the Company’s reports,
      registration statements, proxy and information statements and other information
      that is filed electronically with the SEC are available on:


http://www.sec.gov/cgi-bin/browse-edgar?company=Integrative+Health+Technologies&CIK=ihht&filenum=&State=&SIC=&owner=include&action=getcompany





**Item
      2. Formation of the Business and Historical Summary of Senticore, Inc
      (SNIO)**





The
      Company was incorporated on January 5, 1999 under the laws of the state of
      Delaware as HOJO Holdings, Inc. as an internet professional services firm
      specializing in high end web site development. However, due to the lack of
      success in developing this business model, in April 2003, former management
      resigned and was replaced by a new board and new officers and directors led
      by
      Rohit Patel and the Company was renamed at Senticore, Inc. (SNIO). At the time
      of acquisition by SNIO, HOJO Holdings, Inc. reported that it had 20,000,000
      authorized shares, 4,800,000 issued and outstanding shares, a stockholders’
deficit of $(30,235) and a net operating loss of $(179,720) since
      inception.





SNIO
      sought business opportunities with target businesses that offered significant
      long term growth potential. Although the new management had experience in the
      hospitality industry and real estate, they also sought opportunities in any
      specific business, industry or geographical location for participation in
      business ventures of virtually any kind or nature. Due to SNIO’s limited capital
      resources, it sought the acquisition of, or merger or consolidation with,
      companies that did not need substantial additional capital but that desired
      to
      establish a public trading market for its shares. These companies could,
      therefore, avoid the potential adverse consequences of undertaking a public
      offering, such as the time delays and significant expenses incurred to comply
      with the various federal and state securities laws that regulate initial public
      offerings. These businesses were thought to create a public market for their
      shares in order to enhance liquidity for current shareholders, facilitate
      raising capital through the public sale of securities of which a prior existence
      of a public market for our securities exists, and/or acquire additional assets
      through the issuance of securities rather than for cash.





-
          4
          -




As
      part
      of their business plan, on February 11, 2005 SNIO filed the required Form N-54
      with the SEC electing to be regulated as a Business Development Company (“BDC”)
      in accordance with the Investment Company Act of 1940. The company submitted
      an
      Offering Circular Under Regulation E on February 10, 2005 ultimately issuing
      78,324,075 shares of common stock under the Regulation E exemption.





As
      a
      result of a series of failed acquisitions, business losses, questionable
      issuance of shares for services and collateral surrendered for defaulted loans,
      the absence of any cash flow or operating profits to defer operating expenses,
      multiple changes in auditors and accountants, SNIO reported in its 2005 annual
      filing that it had increased its:





·
            authorized
                shares to 200,000,000,


·
            issued
                and outstanding shares to 181,145,154,


·
            retained
                deficit to $(3,772,359) and


·
            cumulative
                net loss since its January 1999 inception to $(4,482,091).





While
      we
      have verified these figures, due to the incomplete and inconsistent books and
      records we received in conjunction with our acquisition SNIO in June 2006,
      we
      are unable to attest to the accuracy of any the additional information reported
      in the SEC filings and the financial information contained therein. Therefore,
      while the financial statements provided in this report have been prepared by
      a
      certified public accountant, the pre-merger historical information presented
      in
      this filing should be viewed as our estimate, not certification, of the events,
      transactions and financial information that were reported in the quarterly
      and
      annual filings beginning with the quarter ending March 31, 2003 through and
      including the quarter ending June 30, 2006.





In
      a
      complicated series of transaction reported in SNIO’s 2005 annual filing (pgs
      33-35), on October 18, 2005, SNIO acquired 7,000,000 common shares, (as
      converted) in Taj Systems, Inc. (Pink Sheets: TJSS) an on-line gambling company
      trading for $0.25 a share; 11,538 shares of Strategic Growth Ventures, Inc.
      (Pink Sheets: SGWV [later acquired by Beere Financial and reverse split to
      2,307
      shares]), and 882,353 shares of AdZone Research (OTC: ADZR) trading for $.06
      a
      share.





On
      May
      12, 2006, SNIO filed an Form 8-K with the SEC announcing that it planned to
      enter into an Agreement and Plan of Reorganization (the “Agreement”), with
      Integrative Health Technologies, Inc., an Illinois corporation (“IHT”); the
      common stockholders of IHT (the “IHT Stockholders”); and Jay Patel, SNIO’s CEO.
      Pursuant to the terms of the Agreement, all 80,000,000 shares of common stock,
      $.0001 par value, of IHT (the “IHT Common Stock”) issued and outstanding prior
      to the closing, will be exchanged in the aggregate for 20,000,000 shares of
      Series A Convertible Preferred Stock, $.001 par value, of SNIO (the “Convertible
      Preferred Stock”). As a result of the exchange, IHT will become a wholly-owned
      subsidiary of SNIO and the shareholders of IHT will have voting control of
      SNIO.





Each
      share of Convertible Preferred Stock has the right to convert into 400 shares
      of
      SNIO common stock, $.001 par value and the right to vote on an as converted
      basis. The Convertible Preferred Stock is non-participating only with regard
      to
      dividends distributed prior to the conversion. The Certificate of Designation
      of
      the Convertible Preferred Stock was filed with the Secretary of State of
      Delaware and contains certain other covenants to protect the priority of the
      Convertible Preferred Stock, and its claim to assets of SNIO in certain events,
      all of which are set forth in Exhibit A to the Agreement, attached as Exhibit
      10.1 to the 8-K and is hereby incorporated by reference.





SNIO,
      IHT
      and the IHT Stockholders have structured a merger transaction in which the
      holders of the outstanding shares of SNIO’s Common Stock and the IHT
      Stockholders will together become shareholders of SNIO, and their plan is that
      all shareholders shall be provided with an equity participation in SNIO
      equivalent of the dollar value of their equity interests on the date of closing.
      After giving effect to the transaction, SNIO will own all of the issued and
      outstanding shares of IHT and IHT will become a wholly-owned subsidiary of
      SNIO.
      The IHT Stockholders will have voting control of SNIO amounting to approximately
      97.7% of SNIO’s total combined voting powe.





IHT
      is
      engaged in the research and development of healthcare products and technologies,
      and its headquarters are located in San Antonio, Texas. IHT had an unaudited
      balance sheet as of April 30, 2006, presenting total assets of $8,097,515 and
      stockholders equity of $7,710,883. IHT intends to file an amendment to this
      Form
      8-K within 71 calendar days disclosing its audited and pro forma combined
      financial statements with the Registrant, as required by Item 9.01 of Form
      8-K.





As
      previously reported, SNIO filed a Form N-54A with the Commission on February
      11,
      2005 and elected to become a business development company subject to Sections
      55
      through 65, among others, of the Investment Company Act of 1940, as amended.
      As
      a result of this transaction, IHT will become SNIO’s largest portfolio company.
      In addition, the management of IHT will assume management of SNIO after the
      filing of a Schedule 14F-1 with the Commission and the required waiting period.
      The new management intends to continue to operate SNIO as a business development
      company and to make additional acquisitions limited to the healthcare and
      related industries. As a result of the acquisition, SNIO will have an
      181,145,154 shares of common stock issued and outstanding, and 20,000,000 shares
      of Convertible Preferred Stock issued and outstanding.





The
      Agreement closed on June 3, 2006 as reported in a Form 8-K filed with the SEC
      on
      that date and is hereby incorporated by reference.





-
          5
          -




**Item
      3. Current Description of Integrative Health Technology, Inc.’s (IHTI)
      Business**





**A.
      Company Mission** .
      Integrative Health Technologies, Inc’s (IHTI) mission is to use its scientific
      and testing resources, research and development experience, and financial
      resources to aid healthcare companies in the discovery, testing and marketing
      of
      their healthcare products and technologies. In return for this support, IHTI
      receives equity or stock in the companies for whom it provided these services
      or
      royalties from the products and technologies it helped develop.





The
      Company is limiting its involvement to healthcare entities that can provide
      products and services that can contribute to the prevention and reduction of
      the
      global health problems as reported by the World Health Organization
      (WHO):





“Nearly
      400 million people will die from heart disease, diabetes and other chronic
      ailments over the next 10 years, but many of those deaths can be prevented
      by
      healthier lifestyles, diets and increased physical activity. Exercise and better
      diets can help prevent 80 percent of premature cases of heart disease, strokes
      and diabetes... The financial burden from an increasing death toll from such
      non-communicable diseases will also be enormous. China could spend $558 billion,
      Russia, $303 billion and India, $236 billion over the next decade treating
      heart
      disease, strokes and diabetes. ‘The lives of far too many people in the world
      are being blighted and cut short by chronic diseases, diseases that can be
      prevented with healthier diets and increased physical activity’ said Lee
      Jong-Wook, WHO Director-General.”





IHTI’s,
      business plan is to conduct research and development of products, programs
      and
      technologies aimed at enhancing body composition. Improvements in body
      composition are achieved as a result of decreasing body fat while maintaining
      or
      increasing lean mass and bone density. Improvements in these parameters will
      make major contributions to the reduction of risk factors for three major global
      disorders: osteoporosis, obesity and sarcopenia (the progressive loss of lean
      mass with aging and inactivity). All three of these disorders result from
      sub-optimal levels of muscle, fat and bone mass, or a combination of the three.
      Osteoporosis is the result of too little bone mass or density; obesity is the
      result of too much fat mass; and sarcopenia is the result of too little muscle
      mass. Click on the following icons for more information on the Company’s
      progress to date and its potential for future growth. A more detailed
      description of the Company’s mission can be found on www.ihtglobal.com under the
      following headings:





**Scientific
      Advisory Board** - lists
      the current members and their institutional affiliations whom the Company relies
      upon for independent evaluations of its research and development projects and
      programs.





**Strategic
      Alliances** - lists
      and describes the organizations with whom the Company has formed strategic
      alliances.





**Significance
      of Body Composition Measurements** -
      provides information on the importance of using changes in Body Composition,
      instead of changes in scale weight, to evaluate the safety and efficacy of
      medical and nutritional interventions, the research conducted to date, and
      current and future R & D activities.





**On-site
      DEXA Measurements** -
      provides information on Dual Energy X-ray Absorptiometry (DEXA) and why it
      is
      considered the “gold standard” for measuring fat, lean and bone. The Company’s
      mobile testing units have enabled the company to acquire measurements throughout
      the United States and Canada.





**Blood
      Chemistry Testing** -
      describes the typical 43-item blood chemistry panel that has been obtained
      from
      approximately 9,000 subjects who have participated in the company’s research
      studies over the past 30 years and the potential these measurements have to
      expand client research designs and to contribute to the general body of
      scientific information.




**On-going
      R & D** -
      describes the Company’s on-going clinical trials and research and the
      development of health-enhancing and risk-reducing products and
      technologies.





**The
      Database of Medical Biomarkers** -
      contains over two million medical measurements that have been acquired from
      a
      national sample of over 40,000 people of all ages, genders, ethnic backgrounds.
      It includes over 22,000 DEXA tests acquired over the last 30 years.





-
          6
          -




**B.
      Revenue Sources.** IHTI’s
      revenues are being derived from the Strategic Alliances IHTI has established
      with companies to whom it provides technical, testing and scientific support.
      The revenues include:





·
            Sales
                of shares in companies that have been acquired from services provided
                by
                IHTI


·
            Fees
                paid by healthcare companies for the conduct of pilot studies and
                clinical
                trials by Health & Medical Research, Inc.


·
            Royalties
                or overrides from products/technologies for which HealthTech Development,
                LLC provided R & D services


·
            All
                consulting fees and R & D profits earned by Dr. Kaats in his capacity
                as CEO of HealthTech Development,


·
            LLC
                become the property of IHTI to avoid a conflict of interest


·
            Profit
                sharing of as much as 50% for all nutritional products/technologies
                sold
                by HealthTech Products, LLC.


·
            Shared
                profits for services IHTI provides to it’s portfolio companies, e.g.
                Innovative Functional Foods for sales of the bone-health
                cookie


·
            Fees
                for testing and scientific services provided through sub-contracts
                for
                other testing/research agencies





**C.
      Historical Summary of IHTI’s Activities (Includes significant events subsequent
      to the end of the quarter).** Copies
      of
      all SNIO, IHHT and IHTI filings are available on the SEC website cited above
      and
      on the Company’s www.ihtglobal website.





Copies
      of
      all press releases are available on the Company’s website under the icon,
“Company Press Room.”





A
      chronological summary of all filings and press releases is presented
      below.





**May
      12, 2006, SEC Form 8-K SNIO** Announces
      Merger/Reorganization Plan. SNIO announced plan to enter into an Agreement
      and
      Plan of Reorganization (the “Agreement”), with Integrative Health Technologies,
      Inc. (see summary of 8-K above).





**May
      25, 2006 IHT’s Press Release** Announces
      Agreement Providing Description of it’s Business. Integrative Health
      Technologies, Inc. (IHT) of San Antonio announced the signing of a merger
      agreement in which it will become a wholly owned subsidiary of, and transfer
      its
      assets and outstanding **** shares
      to, Senticore, Inc. (OTC Bulletin Board: SNIO), a business development company.
      IHT and its subsidiary, Health and Medical Research Center, have been engaged
      in
      the research and development of nutritional and healthcare products and
      technologies for over 20 years. Relying on the advice and guidance provided
      by
      its highly qualified Scientific Advisory Board (www.ihtglobal.com), IHT receives
      grants from a number of leading companies in the healthcare and nutrition
      industries to conduct independent studies of the safety and efficacy of products
      and supplements designed to facilitate weight loss while improving bone health,
      blood chemistries, and quality of life. Its assets include a national database
      of over 2,000,000 measurements of bone density, lean and fat mass, and blood
      chemistries obtained from some of the most sophisticated **** technologies
      available. It contains data from people residing in every state in the union
      from measurements obtained from IHT's five mobile testing units.





“The
      database is a virtual scientific gold mine for the purpose of examining the
      relationships between the various measurements, and can aid in the development
      of prediction models designed to personalize nutritional and medical
      recommendations to the individual's unique physiological and biochemical
      requirements,” said Dr. Joel Michalek, a university professor on IHT's
      Scientific Advisory Board.





“There
      is
      no doubt that the measurements of changes in lean, fat and bone mass contained
      in the database are going to have a profound effect on how we view weight loss,”
said Dr. Harry G. Preuss, a member of IHT's Scientific Board, Professor of
      Medicine at Georgetown University and former President of the American College
      of Nutrition. “We are re-framing the way we think about weight loss and paying
      much more attention to the kind, not the amount, of weight that is lost.
      Obviously, losing muscle and bone mass is hardly indicative of healthy weight
      loss,” added Dr. Preuss.





The
      company has derived its income from ongoing research and consulting contracts
      with its healthcare and nutritional clientele. As of May 15, 2006, IHT had
      an
      un-audited balance sheet indicating assets of $8,097,515 and liabilities of
      $522,952. “We need to underscore the 'un-audited' nature of these figures until
      we obtain an independent audit, which will be filed as an amendment to our
      Form
      8-K within 71 calendar days of closing,” said IHT's CEO, Gilbert R. Kaats,
      PhD.





IHT
      will
      become Senticore's largest portfolio company and, in conjunction with the
      merger, IHT's management team will replace Senticore's management after the
      SEC's required 10-day waiting period. At that time, the company will continue
      to
      operate as a business development company, but will limit its acquisitions
      and
      its research and development, to the healthcare and nutritional industries
      utilizing its networking connections that have been developed over the past
      20
      years.





-
          7
          -




**June
      3, 2006 SEC Form 8-K** Reports
      Merger/Reorganiztion Agreement Closed. Filed by SNIO announcing closing of
      Merger Agreement and Plan of Reorganization with Integrative Health
      Technologies, Inc. In addition to the conditions set forth in the planned
      Agreement, the final Agreement included an exchange of Taj Systems shares owned
      by SNIO for cancellation of SNIO’s current liabilities by $736,400, a reduction
      from $958,572 to $222,172.





**June
      3, 2006 SEC Form 8-K** Reports
      Change in SNIO’s Board and Officers. In conjunction with announcing the closing
      Agreement, an 8K filed on the same date announced the replacement of SNIO’s
      Board members and officers with IHT’s board members and officers describing
      their qualifications.





**June
      14, 2006 Press Release** Announces
      $736,400 (77%) Reduction of SNIO’s Outstanding Liabilities. SNIO’s incoming CEO,
      Gilbert R. Kaats, PhD, pointed out that “I think it is important for our
      shareholders to know that this was not the result of the investment of
      additional funds,” said Kaats. “We offset these liabilities by providing the
      creditors with preferred shares in Taj Systems, Inc., one of our portfolio
      companies that trades on the Pink Sheets under TJSS. Thus, while our liabilities
      were reduced, so were our assets,” Kaats pointed out. Kaats also reported that
“...even after offsetting the $736,400 of liabilities with Taj shares, SNIO
      retains approximately 4,246,394 shares...”





SNIO's
      new management team will continue to focus their energies on its research and
      development activities, particularly its $1,300,000 grant previously awarded
      to
      IHT Research & Development, Inc., one of SNIO's portfolio companies. This
      grant is to conduct clinical trials involving 400 subjects from ages 8 to 80,
      to
      develop a bone-health program. 'Our inclusion of adolescents in this study
      is in
      direct response to the U.S. Surgeon General's 'call to action' to the healthcare
      industry in light of a study finding that almost 85% of high school girls are
      receiving insufficient amounts of bone-building nutrients for normal growth,'
      said Sam Keith, the R & D company's CEO. 'This nutritional deficiency is
      particularly troublesome,' Keith pointed out, 'since most of the adolescents'
      bone growth occurs during these critical early years.'





**June
      14, 2006 Press Release** Describes
      IHTI’s Bone Health Study. SNIO describes how the Company’s portfolio companies
      are working together on a grant to complete a $1,286,897 study to develop and
      market a bone-health program for adolescents and adults. The grant, jointly
      funded by AlgaeCal International and IHT prior to its merger with SNIO, involves
      400 subjects and is being conducted by investigators from two major
      universities. The study is in response to a 'call to action' issued in the
      U.S.
      Surgeon General's (SG) 2004 Bone Health report citing studies that 85% of
      adolescent girls and 65% of boys do not consume sufficient calcium and bone
      building nutrients for normal bone growth. The SG reported that the lack of
      adequate nutrition during these critical bone-building years has placed
      America's bone health in jeopardy. The Report encourages development of programs
      to increase bone health by improving diets, increasing physical activity, and
      improving 'health literacy' and to '...get started by taking action today in
      homes, health care settings, and communities across our nation...you are never
      too old or too young to improve your bone health,' pointed out the
      SG.





Using
      AlgaeCal's plant-derived calcium with natural occurring magnesium and 73 other
      trace minerals, IHT conducted an exhaustive review of the research on
      bone-building ingredients. This research supported the addition of higher than
      recommended levels of vitamins D-3 and K-2 to the blend and the incorporation
      of
      recently discovered bone-building mineral, strontium, into the adult program.
      The blend was incorporated into bone-health cookies along with Z-trim
      fat-replacer (AMEX: ZTM; health-enhancing Enova oil (www.enovaoil.com), a
      product of a joint venture between Japanese Kao Corporation and Archer Daniels
      Midland; and Fibersol-2 (www.matsutaniamerica.com) soluble dietary fiber. Prior
      to beginning the study, a series of pilot studies were conducted using
      adolescents and adults to evaluate the taste and texture of the cookies using
      increasingly finer grinds of the calcium.





After
      completion of the pilot studies designed to refine the plan, formal clinical
      trials began in early 2006. The trials involved 400 subjects, including adults,
      adolescents and children. Subjects completed self-reports, bone density x-rays
      (DEXA), and a 43-item blood chemistry panel at baseline, and will complete
      the
      same tests after 90-days, 6-months, one-year and five-years. “In addition to the
      benefits derived from the research data,” said Samuel Keith, CEO of the Research
      Center, “the children, adolescents and adults are all being provided with
      comprehensive test reports of their bone density and blood chemistries, the
      cost
      of which would be prohibitive to most of these people.”





“In
      return for their support of our clinical trials,”said Dean Neuls, President of
      AlgaeCal International, “we have a long-term strategic relationship with SNIO
      providing them with a royalty based on our gross national and international
      sales of AlgaeCal as well as the bone-health program we are presently studying.
      “In our view, developing and marketing the bone-health program that incorporates
      the use of bone-health supplements to improve diets, a practical pedometer-based
      program to increase physical activity and feedback of test and tracking data
      to
      improve health literacy is an example of the synergy of our portfolio
      companies,” said Gilbert Kaats, SNIO's CEO.





**June
      22, 2006 Press Release** Announces
      Plan to Change Company’s Name to Integrative Health Technologies, Inc. (IHHT)
      and Dividend AdZone, Inc. (ADZR) shares. SNIO’s first-ever dividend will be
      distributed to all shareholders of record on close of business on June 30,
      2006.
      The amount and timing of the dividend will be based on an estimated at $58,000
      to be derived from sale of its 882,353 shares in AdZone Research, Inc., a
      company incompatible with SNIO’s current mission. The intent to dividend was
      announced by the Company in its 2004 and 2005 SEC filings.





-
          8
          -




**July
      10, 2006 Press Release** Announces
      Company’s First Profitable Quarter Since its Inception in 1999. Reversing a
      7-year history of consistent quarterly losses averaging $150,000 per quarter,
      the Company announced that its net profit for the quarter ending June 30, 2006
      will exceed $500,000. “We are a Business Development Company, or BDC,” explained
      Gilbert R. Kaats, SNIO’s CEO, “and our profit is calculated based on increases
      in the company's net assets from the portfolio companies it acquires. If the
      value of one of our portfolio companies increases, our net profit increases,
      providing the increase is not offset with a corresponding increase in
      liabilities,” Kaats pointed out. The main source of the net profit for this
      quarter was an increase in the value of the shares of Taj Systems, Inc. (Pink
      Sheets: TJSS), one of SNIO’s portfolio companies that trades on the Pink Sheets
      under TJSS.





The
      increase in assets that led to the profit does not include Integrative Health
      Technologies, Inc.'s (IHT) assets which were acquired in the merger. The
      company's May 25th release press release estimated that IHT's assets could
      have
      a value in excess of $7,800,000. “However,” Kaats pointed out that “...we also
      cautioned against using this value for IHT's assets until an independent audit
      is completed later this quarter. We have excluded these assets from our
      calculation of profits,” added Kaats.





**August
      2, 2006 SEC Form 8-K** Reports
      Change in Company’s name to “Integrative Health Technologies, Inc.” (IHHT) and
      Change in Officer/Director. In connection with the name change, Carl Gessner,
      SNIO’s President and Director, resigned from both positions. Gilbert R. Kaats,
      Ph.D., Chairman and CEO of IHHT, assumed the duties of President without any
      increase in compensation for such service, and provided his background
      information.





**August
      22, 2006 SEC Form 10QSB For Quarter Ending June 30, 2006.**





**October
      18, 2006 SEC Form 8-K** Reports
      Plan to Execute a 200:1 Reverse Split of Common Stock and Reduction of Preferred
      Stock Conversion Ratio from 1:400 to 1:2. As a result of the Reverse Split,
      the
      Registrant will have approximately 902,292 shares issued and outstanding, which
      is based on a total issued and outstanding number of shares of 180,458,487
      as of
      September 19, 2006. In addition, as a result of the Reverse Split, the
      Registrant will have a public float of approximately 552,562 shares, which
      is
      based on a total public float of approximately 110,512,320 shares as of
      September 19, 2006. Reducing the conversion ratio of the preferred shares by
      a
      factor of 200 treats holders of Series A Convertible Preferred Stock in the
      same
      way as holders of common stock which will be converted into 40,000,000 shares
      of
      common stock, instead of the 8,000,000,000 shares that would have resulted
      previously.





**October
      18, 2006 SEC Form 8-KA Filed as Amendment to a previously filed 8-K Reporting
      Independent Audit of IHT of Illinois’s Net Assets of $7,626,273 to be Added to
      Assets Acquired from SNIO.**





**Nov
      24, 2006 SEC Preliminary 14-C Filed for Reverse Split and Change in Conversion
      Ratio of Preferred Shares.**





**Dec
      19, 2006 SEC Preliminary 14-C Filed of Company’s Intent to Withdraw its Election
      to be Regulated as a Business Development Company (“BDC”) Under the Investment
      Company Act of 1940.**





**Dec
      21, 2006 SEC Form 10-Q for Quarter Ending September 30, 2006.**




**Feb
      21, 2007 SEC Definitive 14-C Filed for Reverse Split and Change in Conversion
      Ratio of Preferred Shares**





**Feb
      22, 2007 SEC Form 8-K Reports Company’s Concern About the Legitimacy of its’
2005 Election to be Regulated as a BDC.** The
      Company has previously reported on several occasions that it is a Business
      Development Corporation (“BDC”) under the Investment Act of 1940. However, it
      has come to the attention of management that the Company’s election to become a
      BDC was ineffective and that the Company is not and has never been a BDC. On
      February 11, 2005, prior management had caused the company to file Form N-54
      purporting to elect BDC status. Prior management apparently believed that the
      Company had made an effective election to become a BDC, since (1) they operated
      the company on that assumption, (2) represented to current management that
      the
      company was a BDC, and (3) caused the Company to specifically represent such
      in
      the closing documents for the June 3, 2006 transaction. Current management,
      relying on the Form N-54 filing and the representations made prior to and at
      closing, believed the company was a BDC.





Current
      management has discovered that the N-54 filing was ineffective in that it did
      not comply with the preconditions for an effective filing under s.54 of the
      Investment Company Act. Specifically, s.54 of the Investment Company Act
      requires one of two preconditions to be met for an effective BDC election:
      the
      company either must have a class of its equity securities registered under
      section 12 of the Securities Exchange Act of 1934 or it must have filed a
      registration statement pursuant to section 12 of the Securities Exchange Act
      of
      1934 for a class of its equity securities. Neither precondition was met by
      the
      Company.





-
          9
          -




Although
      the mistaken belief as to the company’s status has led to instances of
      noncompliance with certain securities laws and regulations, management is not
      aware of any issues arising as a result that are likely to have a material
      effect on the company or its business prospects. Nevertheless, investors are
      cautioned that the laws and regulations in question are complex, that the
      situation is unusual, and that a full assessment of all the effects and their
      materiality or lack of materiality has not yet been completed.





**Mar
      26, 2007 Nasdaq Executes Previously Reported 200:1 Reverse Split and 1:2 Change
      in Conversion Ratio of Preferred Shares Announced Assigning Company New Trading
      Symbol of IHTI.**





**Mar
      27, 2007 Mannatech Inc. (Nasdaq: MTEX) Announces Award of Grant to IHTI to
      Analyze IHTI’s Extensive Database to Determine the Health Benefits of Mannatech
      Glyconutrients.** Mannatech,
      Incorporated (Nasdaq: MTEX), has awarded a grant to independent researchers
      to
      analyze a database of more than 1 million aging- and immune-related biomarkers
      to determine the relationship between changes in these measurements and the
      consumption of glyconutrients. The database contains biomarkers taken from
      more
      than 7,000 people who have consumed Mannatech's glyconutritional products over
      the last 13 years. It also contains biomarkers taken from more than 13,000
      people who have consumed supplements from other companies during the same
      period. Researchers will compare changes in biomarkers between the two sets
      of
      consumers.





Biomarkers
      are sophisticated medical measurements that are used to track changes in
      biological functions or conditions within the body that relate to aging and
      immunity. Analysis of the database will be conducted by the Health and Medical
      Research Center, a wholly owned subsidiary of Integrative Health Technologies,
      Inc. (OTC Bulletin Board: IHTI).





'The
      database contains measurements from one of the industry's largest and
      longest-running longitudinal trials of the potential benefits of nutritional
      supplements,' said Dr. Harry G. Preuss, one of the researchers and former
      president of the American College of Nutrition. 'Our analyses will also go
      well
      beyond comparisons between glyconutrients and other supplements and will allow
      us to publish some heretofore unknown relationships between the millions of
      state-of-the-art measurements in the database.'





Mannatech
      awarded its first grant to the Research Center in 1994 to examine the effects
      of
      glyconutrient consumption using widely accepted biomarkers for immunity and
      aging. These biomarkers include body fat, lean mass, bone density, blood
      chemistries and self-reported quality of life.





'Our
      initial analysis of the data suggests that consumption of Mannatech's
      glyconutritional supplements may have contributed to positive changes in some
      of
      the important aging and immunity biomarkers,' said Gilbert R. Kaats, Ph.D.,
      the
      team's lead investigator. 'Analyses of these short-term pilot studies in the
      database have indicated these glyconutritionals may help improve bone health,
      help maintain already healthy blood cholesterol levels and improve self-reported
      quality of life.'





'Mannatech
      is eager to analyze scientific information spanning more than a decade of
      consumer use of our products,' said Robert A. Sinnott, Ph.D., Mannatech's chief
      science officer. 'We are confident that statistical analysis of this information
      will add to the growing body of scientific evidence supporting the benefit
      of
      glyconutrients on various parameters of health and well-being.'





Professor
      Joel Michalek, another investigator and co-chairman of the Center for
      Epidemiology/Biostatistics at the University of Texas Health Science Center
      at
      San Antonio, said the analysis could significantly improve scientific
      understanding of biomarkers used to assess health and immunity.





'It
      would
      be difficult to overstate the potential contribution our analyses can make
      to
      science and medicine,' Michalek said. 'Virtually no one has the kind nor the
      magnitude of the sophisticated tests and measurements contained in this
      database, particularly since it is a national sample of subjects. We believe
      dozens of scientific articles will emanate from our analyses.'





Founded
      in 1993, Mannatech is a leading wellness company and a pioneer in the field
      of
      proprietary glyconutritional supplements and wellness products. In 1996, the
      company announced a ground-breaking formulation of a nutritional supplement
      comprised of a unique blend of plant-based saccharides, which are also known
      as
      glyconutrients ('glyco' is the Greek word for 'sweet').





**Apr
      9, 2007 SEC Form 8-K Reports Concern About the Legitimacy of its 2005 Election
      to be Regulated as a BDC Rendered Moot by Shareholders’ Approval to Withdraw its
      Election to be Regulated as a BDC.** On
      February 11, 2005, the Company filed Form N-54 in which it elected to become
      a
      Business Development Corporation (“BDC”) under the Investment Company Act of
      1940. The Company believed that this election was valid and reported that it
      was
      a BDC. However, the Company reported in a Form 8-K filed on February 21, 2007
      that it had discovered an irregularity in the filing of the N-54, and that
      it
      had concluded, as a result, that it was not and had never been a
      BDC.





-
          10
          -




Since
      February 21, 2007, representatives of the Company have been in discussion with
      representatives of the SEC. It is the view of the SEC that the Company’s
      election to become a BDC was a valid election, and that the Company remains
      a
      BDC despite the statements to the contrary contained in the February 21, 2007
      Form 8-K. The Company has decided that it would be in the best interests of
      the
      Company and its shareholders to render the issue moot by filing a notice of
      withdrawal of its BDC election under s.54(c) of the Investment Company Act.
      The
      Company has already filed a preliminary Form 14-C reporting that the decision
      to
      withdraw the election has been approved by the Company’s Board of Directors and
      shareholders and will forthwith file a Definitive 14-C notifying the SEC and
      its
      shareholders of the withdrawal of its BDC status.





**Apr
      10, 2007 SEC Definitive Form 14-C Filed for Withdrawal of BDC
      status**





**Apr
      16 SEC Form 10-K Filed for Year Ending 2006.**





**Apr
      16, 2007 Press Release Provides Update of Company’s Activities Since
      Merger/Reorganization Agreement of June 3, 2006. Integrative Health
      Technologies, Inc.’s Reports Four Profitable Quarters, Increased Assets, Reduced
      Liabilities and New Product Development**





SAN
      ANTONIO, Texas, April 16 - After closing its merger Agreement with Senticore,
      Inc. (SNIO) on June 3, 2006 and installing a new management team and directors,
      Integrative Health Technologies, Inc (IHTI) discovered a number of
      irregularities associated with the Company’s pre-merger 2005 election to be
      regulated as a Business Development Company (BDC). In July 2006, the current
      management decided not to publish any press releases until these irregularities
      could be addressed, a reverse split could be implemented, and shareholder
      approval was obtained to withdraw the Company’s BDC status. Those actions have
      now been completed and this update is being provided to existing and future
      shareholders. All filings and press releases from June 2006 are now, or soon
      will be, available on the Company’s website, www.ihtglobal.com. Since June 2006,
      the Company:





ྊ
      Completed its fourth straight quarter of net profits


ྊ
      Achieved an average quarterly cash flow of $152,000 over the past 4 quarters


ྊ
      Increased its assets to $9,321,531


ྊ
Reduced
      its liabilities to $381,225


ྊ
      Recaptured 40,287,329 shares (22.2%) of the 181,145,154 previously issued and
      outstanding


ྊ
Issued
      no additional shares during the last four quarters nor executed any
      loans


ྊ
      Executed reverse split reducing the common shares from 8,140,857,828 available
      for issuance to 40,704,443


ྊ
      Received a grant from Mannatech, Inc. (Nasdaq: MTEX) to analyze IHTI’s massive
      medical data base


ྊ
      Acquired ownership of 8% of AlgaeCal International
      (www.algaecal.com)


ྊ
      Completed R & D for AlgaeCal/Strontium Pro, Company’s Bone-health Program
      for Healthcare Professionals


ྊ
Signed
      contract with investment relations firm to attract new investors and maintain
      current shareholder base





IHTI
      is
      also nearing completion of its 400-subject study of the effects of the AlgaeCal
      Bone-Health Plan (www.algaecal.com) on the bone density, body fat and lean
      of
      children, adolescents and adults. The study is being conducted in response
      to
      the U.S. Surgeon General’s “Call to Action” upon finding that “America’s bone
      health is in jeopardy” citing a USDA finding that over two-thirds of America’s
      adolescents are not receiving sufficient bone-building nutrients to support
      normal bone growth during a period when over 90% of their bone growth
      occurs.


-
          11
          -





**C.**
            **Markets
                for Registrant’s Common
                Stock**





**Trading
      Price History** .
      Our
      common stock is currently traded on the on the Over the Counter Bulletin Board
      (OTC.BB) currently trading under the symbol “IHTI.” From July 2006 to March 25,
      2007 it traded under the symbol “IHHT.” Prior to July 2006 it traded under the
      symbol SNIO. The table below sets forth the lowest and highest ending trading
      price for the quarters indicated.





**Low**
            
            **High****2004**Quarter
                Ending March 31
            $
                0.080
            
            $
                0.210Quarter
                Ending June 30
            $
                0.040
            
            $
                0.110Quarter
                Ending Sept 30
            $
                0.040
            
            $
                0.150Quarter
                Ending Dec 31
            $
                0.070
            
            $
                0.170**2005**Quarter
                Ending March 31
            $
                0.05
            
            $
                0.12Quarter
                Ending June 30
            $
                0.01
            
            $
                0.06Quarter
                Ending Sept 30
            $
                0.01
            
            $
                0.02Quarter
                Ending Dec 31
            $
                0.01
            
            $
                0.01**2006**Quarter
                Ending March 31
            $
                0.003
            
            $
                0.009Quarter
                Ending June 30
            $
                0.004
            
            $
                0.023Quarter
                Ending Sept 30
            $
                0.008
            
            $
                0.020Quarter
                Ending Dec 31
            $
                0.002
            
            $
                0.009**2007**Quarter
                Ending March 31
            $
                0.002
            
            $
                0.006





These
      market quotations reflect the high and low closing prices as reflected by the
      OTC.BB or by prices, without retail mark-up, markdown or commissions and
      represent actual transactions. Some of the companies that have and are serving
      as market makers for the stock include Knight Equity Markets, L.P.; Hill
      Thompson, Magid and Co., Inc.; Stern, Agee and Leach, Inc.; Citigroup Global
      Markets, Inc.; Newbridge Securities Corporation; Domestic Securities, Inc.;
      Jefferies and Company, Inc.; Wm. V. Frankel & Co., Inc.; and Bear, Stearns
& Co. Inc.





**Dividends.** Although
      we previously announced our plan to dividend cash proceeds from the sale of
      AdZone shares (see June 22, 2006 Press Release above), the SEC suspended trading
      of this stock for ~two weeks due to security violations. After this suspension
      was lifted, the shares began trading at $0.01-$0.02 a share and continue to
      linger in that range. Thus, the cost of issuing this dividend to all
      shareholders would exceed the amount derived from sale of the shares. These
      shares are still being held by the Company pending future increases in share
      value.





**Item
      5. Selected Financial Data**





As
      shown
      in the graph below, absent any revenue generating investments or portfolio
      companies, the Company raised its operating capital from loans and from issuing
      an average of 15.8 million shares a month from the second quarter of 2003 until
      the merger and reorganization Agreement was completed in the second quarter
      of
      2006. Starting in the second quarter of 2006, the Company raised its capital
      from managerial fees received from its portfolio companies and liquidation
      of
      shares in public companies that are incompatible with the Company’s healthcare
      mission. During the third and fourth quarters of 2006 the Company pursued an
      aggressive program of recapturing shares that were to be returned to the Company
      for acquisitions that were not consummated and exchanging shares in its public
      companies for Company shares, thereby reducing the outstanding shares from
      181,145,154 to 144,735,787 as shown below. We are optimistic that further
      reductions will be achieved in the next quarter.




-
          12
          -









-
          13
          -




As
      shown
      in the graphic below, from its inception to the quarter ending March 31, 2006,
      the Company has never reported a net profit for any of the 24 fiscal quarters
      depicted. As shown by the quarterly as well as cumulative curves, these losses
      increased significantly in 2003 when the Company changed its name to Senticore,
      Inc. However, upon becoming Integrative Health Technologies in June 2006, net
      profits were reported for the first time in the previous quarter ending June
      30,
      2006 and in the current quarter. As of the date of this filing, the Company
      achieved another net profit for the quarter ending December 31,
      2006.







-
          14
          -




The
      chart
      below depicts the Company’s net assets (Total Assets minus Total Liabilities) as
      reported in the Company’s filings from the quarter ending December 31, 2002
      though the current quarter. The Company’s liabilities have consistently exceeded
      its assets until the quarter ending December 2005 when assets exceeded
      liabilities—the most dramatic change occurring in the current year with the
      acquisition of Integrative Health Technologies of Illinois’ assets.







-
          15
          -




As
      shown
      in the graph below, the shareholders’ equity remained relative constant from the
      year ending December 31, 1999 up to and through the quarter ending March 31,
      2006. The increase in equity shown for the quarter ending June 30, 2006 resulted
      from an increase in the stock value of the Company’s portfolio companies. The
      increase in the quarter ending September 30, 2006 resulted from the acquisition
      of IHT of Illinois’ assets which increased slightly over the year ending
      December 31, 2006 as a result of an increase in the Company’s
      assets.







-
          16
          -





As
      shown
      in the graph below, from the year ending 2000, the equity per share had
      progressively declined from $0.003 to -0.011 by the end of 2003. At that time,
      share equity increased to $0.002 by the end of 2005 only to decline to $0.0002
      by the second quarter ending June 30, 2006, but to increase over the last two
      quarters of 2006 to $0.001 which has been maintained. Thus, in spite of the
      issuance of 20,000,000 preferred shares (convertible into 8 billion common
      shares) the equity per share increased and been maintain over the last three
      quarters of 2006.





-
          17
          -





**Item
      6. Management’s Discussion and Analysis of Financial Condition and Results of
      Operations**





***Preliminary
      Note Regarding Forward-Looking Statements***





THIS
      DOCUMENT CONTAINS “FORWARD-LOOKING STATEMENTS” WITHIN THE MEANING OF THE PRIVATE
      SECURITIES LITIGATION REFORM ACT OF 1995. PROSPECTIVE SHAREHOLDERS SHOULD
      UNDERSTAND THAT SEVERAL FACTORS GOVERN WHETHER ANY FORWARD - LOOKING STATEMENT
      CONTAINED HEREIN WILL BE OR CAN BE ACHIEVED. ANY ONE OF THOSE FACTORS COULD
      CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE PROJECTED HEREIN. THESE
      FORWARD-LOOKING STATEMENTS INCLUDE PLANS AND OBJECTIVES OF MANAGEMENT FOR FUTURE
      OPERATIONS, INCLUDING PLANS AND OBJECTIVES RELATING TO THE PRODUCTS AND THE
      FUTURE ECONOMIC PERFORMANCE OF THE COMPANY. ASSUMPTIONS RELATING TO THE
      FOREGOING INVOLVE JUDGMENTS WITH RESPECT TO, AMONG OTHER THINGS, FUTURE
      ECONOMIC, COMPETITIVE AND MARKET CONDITIONS, FUTURE BUSINESS DECISIONS, AND
      THE
      TIME AND MONEY REQUIRED TO SUCCESSFULLY COMPLETE DEVELOPMENT PROJECTS, ALL
      OF
      WHICH ARE DIFFICULT OR IMPOSSIBLE TO PREDICT ACCURATELY AND MANY OF WHICH ARE
      BEYOND THE CONTROL OF THE COMPANY. ALTHOUGH THE COMPANY BELIEVES THAT THE
      ASSUMPTIONS UNDERLYING THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN ARE
      REASONABLE, ANY OF THOSE ASSUMPTIONS COULD PROVE INACCURATE AND, THEREFORE,
      THERE CAN BE NO ASSURANCE THAT THE RESULTS CONTEMPLATED IN ANY OF THE FORWARD
      -
      LOOKING STATEMENTS CONTAINED HEREIN WILL BE REALIZED. BASED ON ACTUAL EXPERIENCE
      AND BUSINESS DEVELOPMENT, THE COMPANY MAY ALTER IT’S MARKETING, CAPITAL
      EXPENDITURE PLANS OR OTHER BUDGETS, WHICH MAY IN TURN, AFFECT THE COMPANY'S
      RESULTS OF OPERATIONS. IN LIGHT OF THE SIGNIFICANT UNCERTAINTIES INHERENT IN
      THE
      FORWARD-LOOKING STATEMENTS INCLUDED THEREIN, THE INCLUSION OF ANY SUCH STATEMENT
      SHOULD NOT BE REGARDED AS A REPRESENTATION BY THE COMPANY OR ANY OTHER PERSON
      THAT THE OBJECTIVES OR PLANS OF THE COMPANY WILL BE ACHIEVED.





The
      following discussion and analysis should be read in conjunction with the
      financial statements and Preliminary Note Regarding Forward-Looking Statements
      provided above. The Company is considered to be in the development stage as
      defined in Financial Accounting Standards Board Statement No. 7. This section
      also contains reports of activities and results of operations that occurred
      in
      the current year up to the filing date of this Form and subsequent to the year
      ending December 31, 2006. In some cases, the conditions and results of
      operations are reported without accompanying distinctions between the quarter
      in
      which these activities and events occurred.





***Operating
      Changes***





On
      August
      22, 2006, the Company filed a Form 10-QSB for second quarter of 2006 ending
      June
      30, 2006 reporting the steps taken in conjunction with the reorganization and
      restructuring of the Company. These steps included a cost-cutting plan of
      consolidating executive positions, limiting executive compensation, and
      requiring its portfolio companies to provide the BDC with a percentage of the
      gross receipts to reduce the need to borrow funds and issue stock to raise
      operating capital. The filing also announced that the Company would limit its
      acquisitions to healthcare and nutritional companies to take advantage of its
      managerial experience, testing assets, inventory, established networking
      relationships, and its Scientific and Business Advisory Boards. The filing
      reported the Company’s intention to sell off its holdings in entities unrelated
      to the healthcare industry and to initiate an aggressive program to recapture
      shares that should have been returned to the Company for acquisitions and
      transactions that were not consummated. The filing also cautioned investors
      of
      the market risks posed by the impending conversion of the 20 million preferred
      shares into 8 billion common shares and potential distraction from the Company’s
      mission posed by the heavy demands on executive time and resources posed by
      the
      reorganization and restructuring.





***Previous
      Investment Strategy***





On
      June
      3, 2006 the Company closed the transactions contemplated by the Agreement
      described above in Item 3. One result of that closing was the acquisition of
      portfolio companies in the healthcare and nutritional industries, and the
      installation of a new Chairman and Chief Executive Officer who has extensive
      experience in the healthcare and nutritional industries. Accordingly, the
      Company’s focus from June 3, 2006 forward has been, and continues to be, the
      development of business opportunities in the healthcare and nutritional
      industries.





From
      its
      inception until June 3, 2006, SNIO had invested in, or expended significant
      effort and resources attempting to invest in, diverse industries. These included
      timber interests in Costa Rica and Venezuela, real estate in Florida and Canada,
      a gas station in Illinois, a professional hockey team, a commercial glue
      manufacturer, an internet data-gathering company, a gaming company, and an
      on-line poker company. No cash flow had been generated by these activities,
      and
      the Company had raised its operating capital from loans and by the continual
      issuance of stock. The Company posted losses every quarter since its inception
      in 1999 resulting in a shareholders’ equity deficit or net operating loss of
      ($4,027,479) at the quarter preceding the merger and reorganization Agreement.





-
          18
          -




The
      current management believes that the addition of the new portfolio companies
      and
      the focus on the healthcare and nutritional industries will improve the
      Company’s performance. The financial reports filed herewith indicate that our
      financial performance has already begun to improve. It should be noted, however,
      that management has faced, and continues to face, a number of distractions
      from
      operating the on-going businesses due primarily to the necessity of addressing
      issues that were inherited from the previous management team and due secondarily
      to transitional issues arising from the change in investing and operating
      strategies.





***Changes
      in Investment Strategy and Operating Policies and Actions Taken by Current
      Management***





When
      it
      assumed control on June 3, 2006, our current management team implemented a
      number of significant changes to the Company’s previous investing strategy and
      operating policies. Such were reported in its 10-QSB filing for quarter ending
      June 30, 2006 and summarized above under “ ***Operating
      Changes”*** and
“ ***Previous
      Investment Strategy*** ”.
      During
      the current year, the Company implemented these and other changes including
      what
      management considered the most pressing investment strategy and operating
      policies the Company is facing—to retain or de-elect its status as a BDC and to
      execute a reverse split of its stock. These changes, along with actions taken
      and changes made in this quarter and up to the date of this filing, are
      summarized below:





**Board
      of Directors passed a resolution recommending the Company withdraw its BDC
      status** The
      current management conducted a thorough analysis of the appropriateness of
      remaining a BDC. Based on these considerations and after operating the Company
      as a BDC for the past six months, it is the view of the current management
      and
      the Company’s Board of Directors that it would be in the best interests of the
      Company to de-elect its BDC status. Accordingly, on December 18, 2006 the
      Company filed a Form 14C to effect this change, a copy which is incorporated
      by
      reference herein. Notice was sent to all shareholders in conjunction with this
      filing which will be implemented pursuant to action by written consent of the
      majority of the shareholders.





**Board
      of Directors passed a resolution recommending a reverse split of the Company’s
      stock** After
      conducting an extensive and protracted analysis of the pros and cons of a 200-1
      reverse split in this quarter, the Board decided that it would be in the best
      interest of the company to execute a 200 to 1 split of the Company’s common
      stock and to reduce the conversion ratio accordingly reducing for the Preferred
      shares from 400:1 to 2:1. On October 16, 2006 the Board unanimously authorized
      a
      reverse stock split of its common stock and on October 18, 2006 announced its
      decision by filing Form 8-K subject to approval of the majority of the Company’s
      shareholders. On November 24, the Company filed a preliminary Form 14-C
      information statement with the SEC announcing the Company’s intention to execute
      the reverse split pursuant to action by written consent of approval from the
      majority of its shareholders. The definitive 14-C was filed on April 10,
      2007.





**Board
      of Directors passed a resolution recommending conversion ratio of preferred
      stock from 400:1 to 2:1** To
      insure
      equitable treatment of all shareholders, the Company’s Directors unanimously
      authorized a reduction in the conversion ratio of the Series A Convertible
      Preferred Stock so that each share is convertible into 2 shares of common stock.
      As a result, the 20,000,000 issued and outstanding shares of Series A
      Convertible Preferred Stock will be convertible into 40,000,000 shares of common
      stock, instead of into the 8,000,000,000 shares of common stock that would
      have
      resulted from the previous conversion ratio. This announcement was included
      in
      the Form 14-C information statement reported above.





**Company
      received an independent two-year audit of its portfolio company, IHT-IL** As
      reported on Form 8-K/A filed on October 24, 2006, the acquisition of IHT-IL
      contributed net assets of $7,626,273 to the IHHT group. A comparison to a random
      sample of 300 OTCBB companies suggests that the Company’s net asset value
      exceeds that of 84% of OTCBB companies. Additionally, combining these audited
      assets with the Company’s unaudited Consolidated Balance Sheet as of August 1,
      2006 suggests the Company’s total combined assets are $10,235,140 with $955,234
      Total Liabilities, for a Net Asset Value of $9,279,906.





**IHT-IL’s
      Scientific Advisory Board agreed to serve as IHHT’s Scientific Advisory Board
      After** the
      acquisition of IHT-IL, its Scientific Advisory Board, as listed in Exhibit
      99.2,
      agreed to serve as IHHT’s Scientific Advisory Board. The acquisition of IHT-IL’s
      assets and Scientific Advisory Board brought a new revenue stream to the Company
      from managerial fees from its three portfolio companies as discussed below.
      The
      Scientific Advisory Board is being compensated by our major shareholders at
      no
      expense to the Company.





**Company
      acquired three wholly owned portfolio companies in the healthcare industry** On
      August
      31, 2006 IHHT took title to IHT-IL’s assets and IHHT subsequently transferred
      its testing equipment and its extensive longitudinal database described in
      Exhibit 99.1 hereto to Health and Medical Research, Inc., IHHT’s clinical
      research portfolio company. IHT-IL’s inventory was transferred to HealthTech
      Products, LLC, IHHT’s portfolio company marketing health enhancing products and
      technologies. A third portfolio company, HealthTech Development, LLC, a
      consulting and research and development (“R & D”) company, was acquired at
      no cost at the same time, giving IHHT three wholly-owned portfolio companies
      providing different but highly compatible functions within the healthcare
      industry. A discussion of the current activities and operations of these
      portfolio companies is summarized below under ***“Activities
      of Portfolio Companies”.***





-
          19
          -


**Liabilities
      reduced through exchanging or selling of shares in
      investments**  **unrelated
      to healthcare** At
      closing, the Company held shares in Taj Systems, Inc. (“TJSS”), a public company
      in the on-line gaming business. Since the business of TJSS is unrelated to
      the
      healthcare or nutritional industries, the Company plans to liquidate its
      position in TJSS and to use the proceeds to reduce the Company’s liabilities and
      to acquire the Company’s own shares for cancellation. After execution of its
      current Stock Purchase Agreements and Share Exchange Agreements, the Company
      could reduce all of its current liabilities and still retain 1,090,173 shares
      of
      TJSS to use for operating capital or acquisition of additional portfolio
      companies.





**Plan
      to liquidate all investments unrelated to the healthcare and nutrition
      industries** In
      addition to its shareholdings in TJSS, the Company has shares in other public
      companies resulting from investments made by previous management prior to June
      3, 2006. Included are shares in Adzone Research, Beere Financial and The Justice
      Fund. Over time, management expects to liquidate its position in most or all
      of
      these investments and apply any funds received to debt reduction and to
      investment in core activities in the healthcare and nutritional industries.





**Operating
      expenses for the quarter have been met through managerial fees received from
      its
      portfolio companies** The
      Company did not issue any new shares from June 3, 2006 to the date of this
      filing receiving its operating capital from management fees paid to the Company
      by its portfolio companies. The Company’s requirement that all of its portfolio
      companies provide a percentage of their gross receipts from sales and services
      provided sufficient capital to meet our operating needs this
      quarter.





***Activities
      of Portfolio Companies***





**Health
      and Medical Research, Inc. (“HMR”) A Clinical Research
      Organization**





**Grant
      received for database analyses**


HMR
      received a grant for $42,500 from Mannatech Inc. (NASDAQ:MTEX) to conduct an
      independent analysis of its 12-year 7,000 subject Longitudinal Trial. The
      Company’s scientists will work with Mannatech’s scientists to analyze this data
      in conjunction with the over 1,200,000 medical tests and measurements in our
      database. Preliminary analyses have revealed a number of heretofore unknown
      and
      misunderstood relationships between measures of bone density, body fat, lean
      tissue, blood chemistries and self-reported quality of life that are likely
      to
      be brought to light by these analyses.





**The
      AlgaeCal Bone-Health study**


During
      this quarter, HMR received a $215,400 grant to continue a Bone-Health clinical
      trial that was begun in conjunction with a Research Agreement funded through
      IHT-IL, the company that merged with Senticore on June 3, 2006. The study is
      described in the Study Subject’s Informed Consent provided in Exhibit 10.1. The
      study is examining the safety and efficacy of a Bone-Health Program in response
      to the U.S. Surgeon General’s “call to action” for research to combat growing
      problems in the bone health of Americans of all ages, particularly in children,
      adolescents and an aging population. The program was designed and developed
      by
      IHHT’s R & D portfolio company, HealthTech Development, LLC., (HTD) in
      conjunction with AlgaeCal International ( www.algaecal.com ),
      the
      manufacturer of a plant-derived calcium supplement enhanced with Vitamins D
      & K and magnesium. HTD’s pedometer-based behavior modification program was
      incorporated into the program along with AlgaeCal’s supplement and an additional
      bone-building supplement, strontium citrate.





The
      principal investigator for this study is Dr. Joel Michalek of the University
      of
      Texas’ Health Science Center in San Antonio and the testing and research support
      has been sub-contracted to HMR. The study involves examining changes in bone
      density, body composition, blood chemistries, osteoarthritis, and self-reported
      quality of life in four 100-subject study groups, 400 subjects in all, ranging
      from 8 to 80 years of age. Subjects are participating in one of the four
      different study groups as described below, which are designed to examine the
      effects of the Bone-Health Program on:





**1.**
            **Children
                and adolescents from 8 to 18 years of age**A
                total of 100 children/adolescents are participating in this leg and
                have
                completed a battery of tests at baseline and will repeat these tests
                in 90
                days, 6 months and one year. In addition to recording their daily
                step
                totals each day using HTP’s pedometer program, subjects eat two highly
                palatable bone-health cookies each day. In addition to the AlgaeCal
                calcium, the cookies contain high levels of FiberSol-2 soluble fiber
                (www.matsutani.com),
                Archer Daniels Midland’s Enova Oil ()
                (Studies show that, compared to other cooking and salad oils, less
                EnovaTM
                oil is stored in the body as fat.); and a fat replacement product
                developed by the USDA from corn ().
                The cookies were developed over a year of taste and formulation testing
                by
                IHHT’s R & D portfolio company, HealthTech Development, LLC, who
                retains the rights to the formula and is now working on marketing
                the
                product through the Company’s marketing portfolio, HealthTech Products,
                LLC.


**2.**
            **Pre-
                and post-menopausal women seeking to improve their bone
                health**This group includes mostly pre- and post-menopausal women, including
                women
                who are concurrently following the*Curves
                for Women*workout program.


**3.**
            **Overweight
                subjects following a weight loss plan****Previous
                research has shown that weight loss is typically accompanied by loss
                of
                bone density and lean body mass. This leg is designed to examine
                the
                extent to which augmenting a weight loss program with the bone-health
                program can attenuate or eliminate this counterproductive outcome.
                Subjects in this leg are moderately to excessively overweight and
                are
                participating in a weight loss program that involves replacing at
                least
                one meal a day with a vitamin/mineral enhanced nutritional shake
                mix.
                Women following the*Curves
                for Women*workout
                program**are
                also participating in this leg of the
                study.


**4.**
            **Subjects
                consuming glyconutrient supplements**Participants
                in this group have been taking glyconutrient supplements supplied
                by
                Mannatech, Inc. (,),
                many of whom have previous measurements of bone density that are
                below the
                normal ranges for their age and gender. This leg is designed to examine
                the extent to which the Bone-Health program can improve bone densities
                in
                this group.




-
          20
          -




Preliminary
      results suggest that the Bone-Health program is successful in improving bone
      health, particularly in adolescents and post-menopausal women. If these initial
      findings are supported in the final reports from the universities or independent
      research organizations that conducted the studies, IHHT’s product marketing
      portfolio company, HealthTech Products, LLC, will add the Bone-Health Program
      to
      its inventory of products.





**Glyconutrient
      Longitudinal Trials**





For
      the
      past 12 years, members of the Company’s staff and Scientific Advisory Board have
      been conducting a longitudinal trial of the safety and efficacy of glyconutrient
      supplementation on body composition, blood chemistries and self-reported quality
      of life. Funding for this study has been derived from the grantor, Mannatech
      Inc., and fees paid by the company’s sales associates who have been tracking
      their own changes in these parameters while taking glyconutrient supplements.
      These associates receive their test results at the time they complete the test
      and periodic group reports have been published and reported at sales meetings,
      including a company-wide convention that has been held annually. Fees from
      this
      study have averaged close to $100,000 annually and HMR has now taken over the
      study and will continue to add these results to its database for some time
      to
      come.





**Additional
      clinical trials and study activities**





HMR
      is
      currently involved with preparing protocols or conducting pilot studies for
      a
      number of other clinical trials that may or may not eventuate in grants. These
      studies involve the effects of nutritional supplements on long-distance
      truckers, the growth and development of impoverished children that will be
      housed in the Hobbs House Of Hope in Kitengela, Kenya, Africa, long-distance
      truckers, people suffering with toe fungus, and glucose and hemoglobin levels
      in
      diabetic and pre-diabetic subjects. HMR is currently preparing a manuscript
      for
      publication in a peer-reviewed medical journal reporting the results of a study
      previously completed on the effects of a glucomannan soluble fiber on weight
      loss and compliance. Additionally, during this period, Dr. Kaats and two
      Scientific Board members published an article in the Journal of the American
      College of Nutrition on the effects of a Chitosan fiber on body composition.
      Dr.
      Kaats served as a co-investigator of two studies presented at professional
      meetings reporting results of clinical trials to identify the genetic basis
      of
      obesity. These studies have been submitted for publication in *Major
      Medicine* and *The
      European Journal of Clinical Nutrition.*





**HealthTech
      Development (“HTD”) A Consulting, Research & Development (R&D)
      Company**





**R
      & D of a vitamin D-enhanced bone-building supplement**





A
      number
      of recent studies, including data from the U.S. Centers for Disease Control,
      have suggested increased levels of vitamin D, (almost three times the
      recommended levels of 800 IUs) may provide a variety of health and disease
      prevention benefits without increased adverse effects. HTD has been working
      with
      AlgaeCal International in a joint-venture to develop and test an enhanced
      version of AlgaeCal’s calcium supplement that will include 2,000 IUs of Vitamin
      D—almost the exact level recent studies recommend. The product is scheduled to
      be available for testing in late January, at which time 100 subjects will be
      recruited and tested by HMR, the Company’s clinical trial portfolio company and,
      if found to be safe and efficacious, will be marketed jointly by AlgaeCal
      International and HealthTech Products, LLC, the Company’s product marketing
      portfolio company.





**R
      & D of a corporate/institutional Risk Reduction
      Program**





Development
      of HTD’s *Institutional*  *Risk
      Factor Reduction Program* which
      was completed during this quarter will be presented to the Memorial Medical
      Center of Port LaVaca, Texas for testing early in January 2007. The program
      includes pre- and post-tests of blood chemistries, quality of life, and bone
      density and body fat on site using HTD’s mobile DEXA testing unit. The program
      also includes HealthTech Products’ (HTP’s) vitamin/mineral enhanced meal
      replacement product in conjunction with the pedometer-based behavior
      modification program If successful, it will then be marketed to companies and
      institutions by HealthTech Products, LLC.





**HTD
      program accepted for presentation at continuing education for healthcare
      providers**





HTD’s
      Weight *Management and Risk Factor Reduction Advisors’ Certification
      Course* has been
      accepted by the Proevity Continuing Education Group ( www.proevity.com )
      for
      incorporation into their continuing education program for healthcare providers.
      One presentation was made during this reporting period that received
“outstanding” ratings by participants. Proevity has scheduled others for 2007,
      including a presentation made at a March 2007 convention to be attended by
      over
      7,000 sales associates and healthcare providers.




-
          21
          -





**Research
      for pilot studies developed or under development**





HTD
      is
      currently developing pilot study protocols for several studies examining the
      safety and efficacy of different supplements thought to: (1) reduce stress,
      (2)
      provide appetite control, (3) reduce incontinence, (4) improve glucose control,
      and (5) aid in weight control. Should any of these protocols result in the
      funding of clinical trials, such trials will be conducted by Health and Medical
      Research, Inc. However, while all of these protocols are being developed during
      the reporting period, past experience has taught us that less than half will
      eventually result in funded clinical trials.





**HealthTech
      Products (“HTP”), Marketing Clinically Validated Healthcare
      Products.**





In
      addition to marketing its products and technologies directly to the consumer
      or
      wholesalers, HTP sells its products to the Company’s other two portfolio
      companies, HMR and HTD when they are used in their research studies. The cost
      of
      these products is included in the research study budgets. HTP’s products include
      pedometers, the pedometer-based behavior modification program, a meal
      replacement nutrition drink mix, blenders, and a wide variety of packing
      materials and containers.





***Results
      of Operations***





The
      financial results of our operation during this quarter are summarized in the
      graphs and the supporting comments under FINANCIAL HIGHLIGHTS above. The section
      on *Implementing
      Changes in Investment Strategy and Operating Policies* provides
      a summary of our day to day operations. Additionally, our website ( www.ihtglobal.com )
      provides a copy of this 10-Q and additional information that relates to the *Results
      of Operations* .





**General
      and Administrative Expenses**





We
      had no
      selling, general and administrative expenses other than those shown
      above.





**Other
      Income (Expenses)**





All
      income and expenses received during this quarter is reflected in the financial
      statements shown above.





**Liquidity
      and Capital Resources**





From
      inception (Jan 1999) through June 3, 2006, the Company funded its cash operating
      requirements through the sale of its common stock and loans. That policy was
      abandoned under the new management when operating capital was derived from
      the
      management fees it received from its portfolio companies. All revenues received
      from sales of stock the Company held in companies with operations that were
      incompatible with the Company’s healthcare and nutritional mission were used for
      debt reduction.





**Critical
      Accounting Policies**





The
      preparation of financial statements in conformity with accounting principles
      generally accepted in the U.S., or GAAP, requires the Company to make estimates
      and assumptions that affect the reported amounts of assets and liabilities
      and
      disclosure of contingent assets and liabilities at the date of the financial
      statements and the reported amounts of revenues and expenses during the
      reporting period. Actual results could differ from those estimates. In recording
      transactions and balances resulting from business operations, the Company uses
      estimates based on the best information available. The Company uses estimates
      for such items as depreciable lives and the amortization period for deferred
      income. The Company revises the recorded estimates when better information
      is
      available, facts change or actual amounts can be determined. These revisions
      can
      affect operating results.





The
      critical accounting policies and use of estimates are discussed in and should
      be
      read in conjunction with the annual consolidated financial statements and notes
      included in the latest 10-KSB, as filed with the SEC, which includes audited
      consolidated financial statements for the fiscal year ended December 31,
      2005.


-
            22
            -


**Item
      7. Financial Statements**





**INTEGRATIVE
      HEALTH TECHNOLOGIES, INC.**


*previously
      known as Senticore, Inc.*


(A
      Development Stage Company)


**BALANCE
      SHEET**


FOR
      THE
      YEARS ENDED DECEMBER 31, 2006 AND 2005





**December
                31,****2006**
            
            **2005****Unaudited**
            
            **Audited****As
                IHHT**
            
            **As
                Senticore**ASSETSControlled affiliated issuers at value
            
            
            8,025,144
            
            
            1,338,732Cash and cash equivalents
            
            
            29,685
            
            
            1,252Receivable
            
            
            350,266
            
            
            --Furniture, fixtures, and equipment
            
            
            18,500
            
            
            --Other assets
            
            
            1,234,463
            
            
            --**Total
                Assets**
            
            $
            9,658,058
            
            $
            1,339,984LIABILITIESAccounts
                Payable
            
            
            (313,413
            )
            
            (341,176
            )Notes
                Payable
            
            
            --
            
            
            (303,302
            )Stockholder
                Loans Payable
            
            
            (121,528
            )
            
            (314,058
            )**Total
                Liabilities**
            
            $
            (434,941
            )
            $
            (958,536
            )**NET
                ASSETS**
            
            $
            9,223,117
            
            $
            381,448**NET
                ASSETS consist of:**Preferred
                stock, $0.01 par value, 20,000,000 shares authorized,20,000,000
                issued July 2006
            
            
            200,000
            
            
            --Paid in capital, preferred
            
            
            7,334,837
            
            
            --Common stock, $0.001 par value, 200,000,000 shares authorized,144,735,787
                issued and outstanding
            
            
            144,736
            
            
            181,845Paid in capital, common
            
            
            4,009,031
            
            
            3,972,682Accumulated deficit
            
            
            (2,465,487
            )
            
            (3,773,079
            )**Total
                Net Assets**
            
            $
            9,223,117
            
            $
            381,448Shares Outstanding
            
            
            144,735,787
            
            
            181,145,154**NET
                ASSET VALUE PER SHARE**
            
            $
            0.064
            
            $
            0.002








**Notes
      to Financial Statements presented below and the Selected Financial Data
      presented above are an integral part of these Financial
      Statements.**


-
          23
          -


**INTEGRATIVE
      HEALTH TECHNOLOGIES, INC.**


*previously
      known as Senticore, Inc.*


(A
      Development Stage Company)


**STATEMENTS
      OF OPERATIONS**


FOR
      THE
      YEARS ENDED DECEMBER 31, 2006 AND 2005


**For
                  year ending December 31, 2006**
              **For
                  year ending December 31, 2005**
              **Cumulative
                  Total Since****as
                  IHT, Inc.**
              **as
                  Senticore**
              **Inception****Unaudited**
              **Audited**
              **January
                  5, 1999****INCOME
                  FROM OPERATIONS:**Managerial
                  Fees, Services and Royalties
              $
                  14,872
              $
                  --
              $
                  20,147Total Income
              $
                  14,872
              $
                  --
              $
                  20,147**EXPENSES:**Administrative
                  expenses and fees
              $
                  52,060
              $
                  55,172
              $
                  651,933Stock
                  Based Compensation
              
              $-
                  -
              $
                  2,694,261Loss
                  in equity of LLC
              
              $
                  --
              $
                  181,300Total Expenses
              $
                  52,060
              $
                  55,172
              $
                  3,527,494**NET
                  INVESTMENT INCOME (LOSS)**
              $
                  (37,187)
              $
                  (55,172)
              $
                  (3,507,347)**NET
                  REALIZED GAIN (LOSS) ON INVESTMENTS**
              $
                  234,769
              $
                  --
              $
                  223,769**NET
                  CHANGE IN UNREALIZED GAIN AND LOSSES ON INVESTMENTS
                  (1)**
              $
                  1,109,290
              $
                  --
              $
                  818,090**INCOME
                  (LOSS) BEFORE CUMULATIVE EFFECT OF ACCOUNTING
                  CHANGES**
              $
                  --
              $
                  --
              $
                  --**NET
                  INCREASE (DECREASE) IN NET ASSETS RESULTING FROM
                  OPERATIONS**
              $
                  1,306,872
              $
                  (55,172)
              $
                  (2,465,487)







**Notes
      to Financial Statements presented below and the Selected Financial Data
      presented above are an integral part of these Financial
      Statements.**


-
          24
          -


**INTEGRATIVE
      HEALTH TECHNOLOGIES, INC**


*previously
      known as Senticore, Inc.*


(A
      Development Stage Company)


**STATEMENTS
      OF CHANGE IN NET ASSETS**


FOR
      THE
      YEARS ENDED DECEMBER 31, 2006 AND 2005





**For
                Years Ending****December
                31,**
            
            **December
                31,****2006**
            
            **2005****IHT,
                Inc.**
            
            **as
                Senticore****Unaudited**
            
            **Audited****INCREASE
                (DECREASE) IN NET ASSETS FROM OPERATIONS**Net investment income (loss)
            
            
            (37,187
            )
            
            (55,172
            )Net Realized Gain (Loss) on investments
            
            
            234,769
            
            
            --Net Change in Unrealized Gain (Loss) on investments
            
            
            1,109,290
            
            
            (291,200
            )**NET
                INCREASE (DECREASE) IN NET ASSETS RESULTING FROM
                OPERATIONS**
            
            $
            1,306,872
            
            $
            (346,372
            )**CAPITAL
                STOCK TRANSACTIONS:**Proceeds
                from common stock
            
            
            --
            
            
            458,500Issuance
                of preferred stock (acquisition of companies)
            
            
            7,534,837
            
            
            --Rescission
                of common stock
            
            
            (40
            )
            
            --Rescission
                of deferred compensation
            
            
            
            
            
            314,950**NET
                INCREASE IN NET ASSETS FROM CAPITAL STOCK
                TRANSACTIONS**
            
            $
            7,534,797
            
            $
            773,450**TOTAL
                INCREASE (DECREASE) IN NET ASSETS**
            
            $
            8,841,669
            
            $
            427,078**NET
                ASSETS - BEGINNING OF PERIOD**
            
            $
            381,448
            
            $
            (45,630
            )**NET
                ASSETS - END OF PERIOD**
            
            $
            9,223,117
            
            $
            381,448










**Notes
      to Financial Statements presented below and the Selected Financial Data
      presented above are an integral part of these Financial
      Statements.**


-
          25
          -


**INTEGRATIVE
      HEALTH TECHNOLOGIES, INC**


*previously
      known as Senticore, Inc.*


(A
      Development Stage Company)


**STATEMENTS
      OF CASH FLOWS**


FOR
      THE
      YEARS ENDED DECEMBER 31, 2006 AND 2005





**For
                Years Ending**
            
            **Cumulative****December
                31,**
            
            **December
                31,**
            
            **Total****2006**
            
            **2005**
            
            **Since****as
                IHT, Inc**
            
            **as
                Senticore**
            
            **Inception****Unaudited**
            
            **Audited**
            
            **January
                5, 1999****CASH
                FLOWS FROM OPERATING ACTIVITIES**Net investment income (loss)
            
            $
            (37,187
            )
            $
            (55,172
            )
            $
            (3,809,546
            )Adjustments
                to reconcile net increase (decrease):Add back depreciation & amortization
            
            
            --
            
            
            --
            
            
            24,318Loss on disposal of fixed assets
            
            
            --
            
            
            --
            
            
            6,000Loss in equity of LLC
            
            
            --
            
            
            --
            
            
            109,000Stock based compensation
            
            
            --
            
            
            --
            
            
            2,600,341Stock based interest
            
            
            --
            
            
            23,750
            
            
            495,170Other stock based expenses
            
            
            --
            
            
            --
            
            
            914,174(Increase)
                decrease in prepaid expenses
            
            
            --
            
            
            --
            
            
            --(Increase) decrease in other assets
            
            
            --
            
            
            7,867
            
            
            --(Increase) in available for sale investments
            
            
            --
            
            
            (1,338,732
            )
            
            (1,338,732
            )Increase (decrease) in accounts payable and accrued
                payables
            
            
            (27,763
            )
            
            62,107
            
            
            99,816**NET
                CASH PROVIDED (USED) IN OPERATING ACTIVITIES**
            
            $
            (64,950
            )
            $
            (1,300,180
            )
            
            (899,459
            )**CASH
                FLOWS FROM INVESTING ACTIVITIES**Net
                Proceeds from sale of investments
            
            $
            260,897
            
            $
            -
            
            $
            260,897Net
                Proceeds from sale of assets
            
            
            4,500
            
            
            --
            
            
            4,500Investment
                in Portfolio Company
            
            
            (6,256
            )
            
            --
            
            
            (6,256
            )Goodwill
                acquired (given back to seller due to unwinding)
            
            
            --
            
            
            908,759
            
            
            --Software
                received (given back due to unwinding) in purchase of
                Pokerbook
            
            
            --
            
            
            111,471
            
            
            (18,529
            )(Purchases)
                of property, plant and equipment
            
            
            --
            
            
            -
            
            
            (5,789
            )**NET
                CASH FROM INVESTING ACTIVITIES**
            
            $
            259,141
            
            $
            1,020,230
            
            $
            234,823**CASH
                FLOWS FROM FINANCING ACTIVITIES**Proceeds
                from borrowings under note payable
            
            $
            --
            
            $
            --
            
            $
            669,600Repayments
                under note payable
            
            
            (165,758
            )
            
            (369,600
            )
            
            (785,358
            )Excess
                of outstanding checks over bank balance
            
            
            --
            
            
            3,302
            
            
            3,302Proceeds
                from sale of land
            
            
            --
            
            
            --
            
            
            135,000Incurrence
                (repayment) of advances
            
            
            --
            
            
            189,000
            
            
            --Advances
                from stockholder
            
            
            --
            
            
            --
            
            
            112,413Proceeds
                from issuance of common stock
            
            
            --
            
            
            458,500
            
            
            539,518Other
                capital contributions
            
            
            --
            
            
            --
            
            
            19,846Loan
                repayments
            
            
            --
            
            
            --
            
            
            --**NET
                CASH (USED) IN FINANCING ACTIVITIES**
            
            $
            (165,758
            )
            $
            281,202
            
            $
            694,321**NON-CASH
                FLOW INVESTING ACTIVITIES**Issuance
                of preferred stock (acquisition of companies)
            
            $
            7,534,837
            
            
            --
            
            
            --Acquisitions
                of wholly owned subsidiaries, fixed assets, intangibles and
                liabilities
            
            
            (7,534,837
            )
            
            --
            
            
            --Issuance
                of portfolio holding in exchange for debt reduction
            
            
            677,373
            
            
            --
            
            
            --Debt
                reduction in exchange for portfolio holding
            
            
            (677,373
            )
            
            --
            
            
            --**NET
                NON-CASH INVESTING ACTIVITIES**
            
            $
            --
            
            $
            --
            
            $
            --**INCREASE
                (DECREASE) IN CASH**
            
            $
            28,433
            
            $
            1,252
            
            $
            29,685**CASH,
                Beginning of Period**
            
            $
            1,252
            
            $
            --
            
            $
            --**CASH,
                Ending of Period**
            
            $
            29,685
            
            $
            1,252
            
            $
            29,685








**Notes
      to Financial Statements presented below and the Selected Financial Data
      presented above are an integral part of these Financial
      Statements.**


-
          26
          -


**INTEGRATIVE
      HEALTH TECHNOLOGIES, INC**


*previously
      known as Senticore, Inc.*


(A
      Development Stage Company)


**STATEMENTS
      OF STOCKHOLDERS' DEFICIT**


FOR
      THE
      YEARS ENDED DECEMBER 31, 2006 AND 2005





Series
                A
            
            Series
                A
            
            Additional
            
            Deferred
                StockCommon
            
            Common
            
            Paid-in
            
            and
                Interest
            
            Preferred
            
            Preferred
            
            RetainedShares
            
            Stock
            
            $Capital
            
            Compensation
            
            Shares
            
            Stock
            
            Deficit(000's)
            
            
            
            
            
            
            
            (000's)Balances,
                December 31, 2003
            
            
            40,040
            
            
            40,040
            
            $
            492,256
            
            $
            (314,950
            )
            
            
            
            
            
            
            $
            (881,670
            )Shares
                canceled
            
            
            (12,000
            )
            
            (12,000
            )Amortization
                of deferred compensation
            
            
            
            
            
            
            
            
            
            
            
            291,200Issuance
                of stock for services
            
            
            21,841
            
            
            21,841
            
            
            2,107,417Issuance
                of stock for interest, payable, acquisitions
            
            
            74,150
            
            
            74,150
            
            
            971,603**Net
                Income (Loss) for the year**
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            $
            (2,835,517
            )Balances,
                December 31, 2004
            
            
            124,031
            
            
            124,031
            
            $
            3,571,276
            
            $
            (23,750
            )
            
            0
            
            $
            --
            
            $
            (3,717,187
            )Issuance
                of stock for cash
            
            
            34,727
            
            
            34,727
            
            $
            401,386Issuance
                of stock for services
            
            
            22,387
            
            
            22,387Amortization
                of deferred compensation
            
            
            
            
            
            
            
            
            
            
            $
            23,750**Net Income (Loss) for the year**
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            $
            (55,172
            )Balances,
                December 31, 2005
            
            
            181,145
            
            
            181,145
            
            $
            3,972,662
            
            $
            --
            
            
            0
            
            $
            --
            
            $
            (3,772,359
            )Correction
                of an error
            
            
            
            
            
            
            
            
            20Shares
                canceled
            
            
            (36,409
            )
            
            (36,409
            )
            
            36,349Issuance
                of stock for acquisitions
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            20,000
            
            $
            7,334,837**Net
                Income (Loss) for the year**
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            $
            1,306,872Balances,
                December 31, 2006
            
            
            144,736
            
            $
            144,736
            
            $
            4,009,031
            
            $
            --
            
            
            20,000
            
            $
            7,334,837
            
            $
            (2,465,487
            )










**Notes
      to Financial Statements presented below and the Selected Financial Data
      presented above are an integral part of these Financial
      Statements.**





-
            27
            -




**ITEM
      8. NOTES TO FINANCIAL STATEMENTS**





***Formation
      (See Items 2 and 3 above)***


***Business
      Description (See Items 2 and 3 above)***





**A.** ***Development
      Stage.*** IHTI
      is
      considered to be in the development stage as defined in Financial Accounting
      Standards Board Statement No. 7, and accordingly, most of its accounting
      policies and procedures have not yet been established.





**B.** ***Basis
      of Presentation.*** Our
      accompanying unaudited financial statements have been prepared in accordance
      with accounting principles generally accepted in the United States of America
      for interim financial information and the instructions to Form 10-Q and Article
      6 of Regulation S-X of the Securities and Exchange Commission (the "SEC").
      Accordingly, these financial statements do not include all of the footnotes
      required by generally accepted accounting principles. In our opinion, all
      adjustments (consisting of normal and recurring adjustments) considered
      necessary for a fair presentation have been included. The balance sheet at
      December 31, 2006 has been derived from the un-audited financial statements
      due
      to the unavailability of adequate books and records in the current year as
      well
      as in previous years provided to the current management since the merger and
      reorganization agreement in June 2006. While we are confident that the financial
      information reported from the closing until the end of this fiscal year, all
      financial information reported prior to June 3, 2006 should be viewed with
      caution and as our best estimates from the information available to us.





***C*** **.
      Management’s Use of Estimates.** The
      preparation of financial statements in accordance with accounting principles
      generally accepted in the United States of America requires us to make estimates
      and assumptions that affect the reported amounts of assets and liabilities
      and
      the disclosure of contingent assets and liabilities at the date of the financial
      statements. The reported amounts of revenues and expenses during the reporting
      period may be affected by the estimates and assumptions we are required to
      make.
      Actual results could differ from our estimates.





**D** ***.
      Stock-Based Compensation.*** We
      are a
      Business Development Company governed by, among other things, Sections 54 to
      65
      of the Investment Company Act of 1940, as amended. As such, the issuance of
      stock for services is generally prohibited. Although certain limited stock
      based
      compensation plans are permissible, no stock based compensation has been
      provided for the year ending December 31, 2006.





**E.** ***Valuation
      of Long-Lived and Intangible Assets.*** The
      recoverability of long-lived assets requires considerable judgment and is
      evaluated on an annual basis or more frequently if events or circumstances
      indicate that the assets may be impaired. As it relates to definite life
      intangible assets, we apply the impairment rules as required by SFAS No. 121,
      "Accounting for the Impairment of Long-Lived Assets and Assets to be Disposed
      Of" as amended by SFAS No. 144, which also requires significant judgment and
      assumptions related to the expected future cash flows attributable to the
      intangible asset. The impact of modifying any of these assumptions can have
      a
      significant impact on the estimate of fair value and, thus, the recoverability
      of the asset.





**F.** ***Earnings/(Loss)
      Per Share.*** We
      compute net earnings/(loss) per share in accordance with SFAS No. 128 "Earnings
      per Share” (“SFAS No. 128”) and SEC Staff Accounting Bulletin No. 98 ("SAB 98").
      Under the provisions of SFAS No. 128 and SAB 98, basic net earnings/(loss)
      per
      share is computed by dividing the net earnings/(loss) available to common
      stockholders for the period by the weighted average number of common shares
      outstanding during the period. Diluted net earnings/(loss) per share is computed
      by dividing the net earnings/(loss) for the period by the weighted average
      number of common and common equivalent shares outstanding during the period.
      For
      this purpose, each share of Series A Convertible Preferred Stock was treated
      as
      400 common equivalent shares.




**G.** ***Income
      Taxes.*** In
      its
      Form 10-KSB for the fiscal year ending 2002 the Company reported that it had
      available net operating loss carry-forwards for income tax purposes of
      approximately $82,400. In its Form 10-KSB/A for the fiscal year ending 2003
      the
      company reported a “...net operating loss carry-forwards of approximately
      $494,500”. However, while the Company failed to file its 2003, 2004 and 2005 tax
      returns, its net operating losses during these years will most likely
      significantly increase these carry-forwards precluding any taxes due for these
      years. Even with the limitation posed by “change in control” or the Company’s
      failure to file the required IRS Forms 1099 for these years, it is doubtful
      that
      the Company will owe any taxes. The Company has employed a CPA to file these
      taxes and we are now aggressively seeking sufficient records and general ledgers
      to file these tax returns and the required IRS Forms 1099 associated with the
      filings.





-
          28
          -




**H.** ***Related
      Party Transactions*** **.** On
      August 15, 2006 The Company entered into an agreement with an investment company
      to purchase sufficient shares of the Company’s stock in Taj Systems, Inc., a
      pink-sheet company trading under the symbol TJSS, to eliminate all of the
      Company’s $671,927 outstanding liabilities that it had at closing. The TJSS
      shares in question are restricted shares, but could be converted into common
      stock as of August 31, 2006. However, the agreement is not contingent upon
      this
      convertibility. The investor provided an initial payment of $114,969 and agreed
      to pay for this stock in five payments over the next five months (as of this
      filing date, all five payments have been received.) Upon receipt of all
      payments, the Company has agreed to transfer these restricted shares to the
      investor. The Board of Directors has approved the sale with the restriction
      that
      all proceeds must be used for the reduction of outstanding debts, and not for
      operating capital or executive or consultant compensation. This sale of TJSS
      stock has the added advantage of being consistent with the Company’s current
      business plan to sell any stock or holdings in portfolio companies, such as
      Taj
      Systems, an on-line gaming company, that are inconsistent with the Company’s
      business plan of limiting its investments and involvement to the healthcare
      and
      nutritional industries. Various stockholders have advanced funds to us from
      time
      to time in prior periods but all such advances have now been paid in
      full.





**Item
      9** ***.
      Subsequent Events*** **.** Significant
      and material events and transaction subsequent to December 31, 2006 have been
      reported above in Item 3.





***Exchange
      of Assets for Liabilities***


The
      Company has exchanged and is continuing to exchange its restricted shares of
      Taj
      Systems, Inc. for IHHT shares due to the inconsistency between the Taj Systems
      on-line poker company and the healthcare goals of IHTI and the current
      management’s lack of experience in the on-line poker industry.





**Item
      10.**  **Quantitative
      and Qualitative Disclosures about Market Risk**





(1)
            **Reverse
                Stock Split**On
                October 16, 2006, the Board of Directors and our majority shareholder
                authorized a 1:200 reverse stock split of the common stock. The Definitive
                Information Statement on Schedule 14C was filed on February 21, 2007
                and
                became effective on March 26, 2007 and is incorporated herein by
                reference.





(2)****
            **The
                impending issuance of 40 million shares**To
                acquire IHT-IL as a wholly owned subsidiary in conjunction with our
                merger
                and reorganization plan, Senticore issued IHT-IL 20,000,000 preferred
                shares each with the right to convert to 400 shares of common stock.
                However, instead of converting the preferred shares into 8 billion
                common
                shares, the conversion ratio was changed from 1:400 to 1:2 converting
                the
                20,000,000 preferred shares into 40,000,000 common
                shares.





(3)
            **Uncertainties
                of reorganization and restructuring**We
                are continuing to implement a new strategy and new policies as part
                of the
                reorganization and restructuring which began on June 3, 2006. Such
                activities always carry risk as they can place a heavy burden on
                management time, they require expenditures, and there is never assurance
                that new strategies or policies will succeed as
                planned.





(4)
            **Uncertainties
                of the effects of de-electing the Company’s BDC status**




**Independence
      of Directors** If the
      election to be treated as a BDC is withdrawn, shareholders may be adversely
      affected. The shareholders’ rights that will be lost include a requirement that
      a majority of the Board of Directors be independent of management; the Company
      will no longer have restrictions on investments and stock issuance; and officers
      and directors can receive stock of the Company.




**Past
      Violations not cured by withdrawing election** Approval
      of the withdrawing of the election to be treated as a BDC does not cure any
      past
      violations that may have occurred. If there were any violations of the
      securities laws, remedies for shareholders can include a rescission of a
      shareholder's investment, fines and penalties, and removal of officers and
      directors from office.





(5)
            **Uncertainties
                of the effects of  unresolved issues inherited from the previous
                management**Since
                taking over management of the Company on June 3, 2006, current management
                has uncovered a****number
                of issues that were unresolved by the previous management, some of
                which
                are contrary to representations made in the Closing and Merger and
                Reorganization Agreement.  Although we have resolved some of these
                issues, many remain unresolved.  Investors bear the risk that all
                unresolved issues inherited from previous management have yet to
                be
                identified.  There is also a risk that some or all of these issues
                may be incapable of resolution.  There is also a risk that some or
                all of these issues may be more serious than they appear at this
                time, or
                they may be more costly to resolve than expected, or
                both.




-
          29
          -




(6)
            **General
                Nature of Unresolved Issues**The general nature of these unresolved issues are gaps in record-keeping
                and apparent instances of regulatory non-compliance. Among other
                things,
                they affect the Company’s tax compliance, its SEC record-keeping
                requirements, and its shareholder list. A non-exhaustive selection
                of
                examples is set forth below:





1)
            Despite
                a representation by previous management to the contrary, no income
                tax
                returns have been filed since Senticore acquired HOJO Holdings in
                March
                2003.





2)
            The
                state of the Company’s records has not allowed current management to
                ensure that all of the required IRS Forms 1099 for stock based
                compensation and contract labor have been
                filed.





3)
            As
                of the date of this filing and despite repeated requests made to
                the
                Company’s previous management and accountants, we have yet to receive
                General Ledger information for the period from March 2003 to March
                2004
                sufficient to allow current management to demonstrate that the Company
                is
                in compliance with SEC record-keeping
                requirements.





4)
            The
                state of the Company’s records does not allow current management to
                confirm that a share log has been maintained that conforms to SEC
                record-keeping requirements and that allows current management to
                answer
                questions that have arisen with respect to the proper number of shares
                outstanding.  These questions include whether shares were issued for
                inadequate consideration, whether shares were issued in violation
                of
                regulations applicable to BDCs, and whether shares that were to be
                held in
                escrow were in fact so held, and if so, whether the terms of the
                escrows
                were complied with.  The questions concerning inadequate
                consideration arise mainly in connection with a lack of record-keeping
                that would allow a reconciliation of the Company’s financial records to
                its records of issued shares, and in connection with a lack of
                record-keeping that would accurately track loan proceeds said to
                have been
                received but not repaid relating to loans for which shares were issued
                as
                collateral.  The questions concerning BDC regulations arise because
                BDCs are prohibited from issuing shares to pay for services rendered,
                and
                the Company may have issued such shares while it was a BDC.  The
                escrow questions arise because shares were issued to various parties
                to be
                held in escrow pending the completion of acquisitions that were never
                consummated (the Westar and Smith-Forestal transactions), and these
                shares
                were not returned to the Company, and it appears that these shares
                should
                have been returned to the Company once it became clear that the
                transactions would not close.





5)
            The
                minutes of the meetings of the Company’s Board of Directors for periods
                prior to June 3, 2006 appear to be
                incomplete.





6)
            The
                state of the Company’s records does not allow current management to fully
                understand the history of the Company’s relationship to Taj Systems, Inc.
                (“TJSS”) and the history of prior management’s relationship to TJSS. 
                The President and CEO of TJSS are the former President and CEO of
                the
                Company and assumed these positions while serving in the same capacity
                with the Company.  From public filings made before current management
                became involved with the Company on June 3, 2006, it appears that
                the
                Company at one time acquired approximately 44 million shares of TJSS
                representing 40% of TJSS issued stock.  For reasons unclear to
                current management, it appears that the Company subsequently exchanged
                its
                40% ownership interest in TJSS for a certificate representing 1.4
                million
                convertible preferred shares of TJSS, each convertible to 5 shares
                of
                common stock representing a total of 7 million shares of common stock
                on
                an “as converted” basis.  Since the certificate is for restricted
                shares, it cannot be converted into free-trading shares until August
                31,
                2007. Although, these shares could have been converted into free-trading
                common stock under Rule 144 exemption on August 31, 2006, TJSS management
                has been unresponsive to our repeated demands to approve the Rule
                144
                exemption.





**Item
      11.**  **Controls
      and Procedures**





**Quarterly
      Evaluation of Controls**





As
      of the
      end of the period covered by this quarterly report on Form 10-Q, we evaluated
      the effectiveness of the design and operation of (i) our disclosure controls
      and
      procedures ("Disclosure Controls"), and (ii) our internal control over financial
      reporting ("Internal Controls"). This evaluation ("Evaluation") was performed
      by
      our Chairman and Chief Executive Officer, Gilbert R. Kaats, ("CEO/CFO"). In
      this
      section, we present the conclusions of our CEO/CFO based on and as of the date
      of the Evaluation, (i) with respect to the effectiveness of our Disclosure
      Controls, and (ii) with respect to any change in our Internal Controls that
      occurred during the most recent fiscal quarter that has materially affected,
      or
      is reasonably likely to materially affect our Internal Controls.





-
          30
          -




**CEO/CFO
      Certifications**





Attached
      to this annual report, as Exhibits 31.1 and 31.2, are certain certifications
      of
      the CEO/CFO, which are required in accordance with the Exchange Act and the
      Commission's rules implementing such section (the "Rule 13a-14(a)/15d-14(a)
      Certifications"). This section of the annual report contains the information
      concerning the Evaluation referred to in the Rule 13a-14(a)/15d-14(a)
      Certifications. This information should be read in conjunction with the Rule
      13a-14(a)/15d-14(a) Certifications for a more complete understanding of the
      topic presented.





**Disclosure
      Controls and Internal Controls**





Disclosure
      Controls are procedures designed with the objective of ensuring that information
      required to be disclosed in our reports filed with the Commission under the
      Exchange Act, such as this annual report, is recorded, processed, summarized
      and
      reported within the time period specified in the Commission's rules and forms.
      Disclosure Controls are also designed with the objective of ensuring that others
      make material information relating to the Company known to the CEO/CFO,
      particularly during the period in which the applicable report is being prepared.
      Internal Controls, on the other hand, are procedures which are designed with
      the
      objective of providing reasonable assurance that (i) our transactions are
      properly authorized, (ii) the Company's assets are safeguarded against
      unauthorized or improper use, and (iii) our transactions are properly recorded
      and reported, all to permit the preparation of complete and accurate financial
      statements in conformity with accounting principals generally accepted in the
      United States.





**Limitations
      on the Effectiveness of Controls**





Our
      management does not expect that our Disclosure Controls or our Internal Controls
      will prevent all error and all fraud. A control system, no matter how well
      developed and operated, can provide only reasonable, but not absolute assurance
      that the objectives of the control system are met. Further, the design of the
      control system must reflect the fact that there are resource constraints, and
      the benefits of controls must be considered relative to their costs. Because
      of
      the inherent limitations in all control systems, no evaluation of controls
      can
      provide absolute assurance that all control issues and instances of fraud,
      if
      any, within the Company have been detected. These inherent limitations include
      the realities that judgments in decision-making can be faulty, and that
      breakdowns can occur because of simple error or mistake. Additionally, controls
      can be circumvented by the individual acts of some persons, by collusion of
      two
      or more people, or by management override of the control. The design of a system
      of controls also is based in part upon certain assumptions about the likelihood
      of future events, and there can be no assurance that any design will succeed
      in
      achieving its stated objectives under all potential future conditions. Over
      time, control may become inadequate because of changes in conditions, or because
      the degree of compliance with the policies or procedures may deteriorate.
      Because of the inherent limitations in a cost-effective control system,
      misstatements due to error or fraud may occur and not be detected.





**Scope
      of the Evaluation**





The
      CEO/CFO's evaluation of our Disclosure Controls and Internal Controls included
      a
      review of the controls' (i) objectives, (ii) design, (iii) implementation,
      and
      (iv) the effect of the controls on the information generated for use in this
      annual report. In the course of the Evaluation, the CEO/CFO sought to identify
      data errors, control problems, acts of fraud, and they sought to confirm that
      appropriate corrective action, including process improvements, was being
      undertaken. This type of evaluation is done on a quarterly basis so that the
      conclusions concerning the effectiveness of our controls can be reported in
      our
      quarterly reports on Form 10-Q and annual reports on Form 10-K. The overall
      goals of these various evaluation activities are to monitor our Disclosure
      Controls and our Internal Controls, and to make modifications if and as
      necessary. Our external auditors also review Internal Controls in connection
      with their audit and review activities. Our intent in this regard is that the
      Disclosure Controls and the Internal Controls will be maintained as dynamic
      systems that change (including improvements and corrections) as conditions
      warrant.





Among
      other matters, we sought in our Evaluation to determine whether there were
      any
      significant deficiencies or material weaknesses in our Internal Controls, which
      are reasonably likely to adversely affect our ability to record, process,
      summarize and report financial information, or whether we had identified any
      acts of fraud, whether or not material, involving management or other employees
      who have a significant role in our Internal Controls. This information was
      important for both the Evaluation, generally, and because the Rule
      13a-14(a)/15d-14(a) Certifications, Item 5, require that the CEO/CFO disclose
      that information to our Board (audit committee), and to our independent
      auditors, and to report on related matters in this section of the annual report.
      In the professional auditing literature, "significant deficiencies" are referred
      to as "reportable conditions". These are control issues that could have
      significant adverse affect on the ability to record, process, summarize and
      report financial data in the financial statements. A "material weakness" is
      defined in the auditing literature as a particularly serious reportable
      condition where the internal control does not reduce, to a relatively low level,
      the risk that misstatement cause by error or fraud may occur in amounts that
      would be material in relation to the financial statements and not be detected
      within a timely period by employee in the normal course of performing their
      assigned functions. We also sought to deal with other controls matters in the
      Evaluation, and in each case, if a problem was identified; we considered what
      revisions, improvements and/or corrections to make in accordance with our
      ongoing procedures.





-
          31
          -




**Conclusions**





Based
      upon the Evaluation, the Company's CEO/CFO has concluded that, subject to the
      limitations noted above, our Disclosure Controls are effective to ensure that
      material information relating to the Company is made known to management,
      including the CEO/CFO, particularly during the period when our periodic reports
      are being prepared, and that our Internal Controls are effective to provide
      reasonable assurance that our financial statements are fairly presented in
      conformity with accounting principals generally accepted in the United States.
      Additionally, there has been no change in our Internal Controls that occurred
      during our most recent fiscal quarter that has materially affected, or is
      reasonably likely to affect, our Internal Controls.





**Item
      12. Directors and Executive Officers of the Registrant**





**Gilbert
      R. Kaats, PhD, Chairman of the Board and Chief Executive
      Officer**





As
      of the
      closing, Gilbert R. Kaats, PhD became Chairman of the Board of Directors and
      Chief Executive Officer of the Company. Dr. Kaats has a PhD in behavioral
      psychology and is currently the executive director of Health and Medical
      Research Center, an independent research entity that conducts clinical trials
      and provides consulting for health-enhancing products and technologies for
      the
      health care and nutritional supplement industries. Grantors for these studies
      have included some of the largest nutritional and dietary supplement companies
      in the world, at least one of which has commissioned a 10-year longitudinal
      trial. Over the past 20 years, Dr. Kaats has developed networking relationships
      with many companies and individuals that will enhance his contributions to
      the
      Company into which the Research Center is merging, with respect to the
      Healthcare and Nutrition Industries





Working
      with a team of investigators from leading universities and research
      organizations, the Center has conducted over 40,000 body composition (% fat)
      and
      bone density tests using the latest and most accurate scientific technologies.
      The Research Center’s database now contains body composition measurements from
      Dual Energy X-ray Absorptiometry (DEXA) on over 19,000 study participants of
      all
      ages from virtually every state in the Union, as well as from five Canadian
      Provinces.





In
      addition to his research background, Dr. Kaats served in the United States
      Air
      Force from 1954 until he retired as Lieutenant Colonel in 1974. While in the
      Air
      Force, Dr. Kaats received a B.A. in psychology, with High Honors, from the
      University of Maryland in 1964; an M.A. in psychology from George Washington
      University in 1965; and a Ph.D. in psychology from the University of Colorado
      in
      1969.





During
      his 20-year military career, he served for five years on the Presidential Flight
      as a navigator on Air Force Two and subsequently as an associate professor
      and
      Director of Research at the Air Force Academy. During the Viet Nam conflict,
      he
      served as a combat crew navigator and received the Air Medal with three oak
      leaf
      clusters. He completed his career on a General Officer's staff where he was
      responsible for the development and supervision of the Air Force’s programs for
      equal opportunity and treatment, race relations, rehabilitation of substance
      abusers, training of substance abuse counselors, and other behavior modification
      programs. A highly decorated officer, Dr. Kaats has, from the beginning of
      his
      Air Force career, occupied positions of leadership and management that have
      provided him with experiences that are relevant to both the business and
      scientific worlds.





**Samuel
      C. Keith, Nominee for Director**





Sam
      Keith
      graduated from the University of the Incarnate Word with a Business
      Administration degree in Management Information Systems. He began his career
      with Mueller and Associates in San Antonio, Texas as a staff accountant. He
      prepared tax returns for corporations, partnerships and individuals. He
      subsequently was tasked with installing computer and information technology
      systems for clients of the firm. He continued his career into network management
      for the national chain of La Quinta Motor Inns, where he aided in system
      upgrades and installations for over 200 hotel units. In 1994, he began working
      with Health and Medical Research Center, an independent research entity that
      conducts clinical trials and provides consulting for health-enhancing products
      and technologies for the health care and nutritional supplement industries.
      Among his responsibilities as Assistant Director, he oversaw the company’s
      information technology and computer systems and coordinated clinical
      trials.





In
      2004,
      he accepted the position of Practice Administrator for Alamo Neurosurgical
      Institute, a start-up neurosurgery practice. From the inception of the practice,
      he established and managed the physician contracts, insurance contracts, billing
      and collections, hospital relations, marketing, and human resources. He also
      implemented a paperless medical office utilizing the latest electronic medical
      record (EMR) and electronic billing software. In February of 2006, he was
      offered the position of CEO at Health & Medical Research Center, where he
      his currently holding this position.





-
          32
          -




**Mr.
      Ovidio Pugnale, Nominee for Director**





Ovidio
      Pugnale was born in Northern Italy in 1933 and immigrated to America in 1935
      with his mother and sister. He grew up in Northeastern Ohio where he attended
      the same public school for all 12 years. Mr. Pugnale entered the United States
      Air Force in 1954 as an Aviation Cadet and retired in 1980 as a Colonel. During
      his career, he accumulated nearly 7,000 hours of flying time as a Navigator
      and
      as an Aircraft Commander on B-52s. He also served as B-52 squadron commander,
      as
      Deputy Commander for Operations for 68 th Strategic Bombardment Wing and Director for Computer Operations for Air Force
      Logistic Command.





Upon
      retirement from the Air Force, he entered the business world as a Plant Manager
      and later buyer of that business. He bought two other highly successful
      businesses and integrated them into the existing business. In 1997, his business
      was a part of a merger/acquisition and eventual IPO. He is currently working
      with his son to develop a videography business. Mr. Pugnale graduated from
      the
      Air War College, earned an undergraduate degree from the University of Omaha
      and
      an MBA from Auburn University.





**Item
      13. Security Ownership of Certain Beneficial Owners and Management Owners of
      5%
      or more of the common stock (as converted after the reverse split) of
      Integrative Health Technologies, Inc.**


There
      are
      only three beneficial owners of 5% or more of the Company stock known at this
      time:





Gilbert
                R. Kaats, PhD
              121
                Newbury Terrace, San Antonio, TX 78209
            
            16,000,000
                shares
            
            38.35
                % of common stockShirlie
                Kaats
              121
                Newbury Terrace, San Antonio, TX 78209
            
            5,000,000
                shares
            
            11.99
                % of common stockThe
                Gale Trust
              3346
                Commercial Avenue, Northbrook, IL 60062
            
            4,000,000
                shares
            
            9.59
                % of common stock





**Item
      14** .
      Unregistered Sale of Equity Securities and Use of Proceeds ****





None.





**Item
      15** .
      Defaults Upon Senior Securities





None.





**Item
      16.** Submission of Matters to a Vote of Security Holders





One
      Form
      14C to reduce the number of authorized shares from 200,000,000 to 50,000,000
      which has been approved by the Company’s Board of Directors and the Majority of
      its current shareholders. It will be submitted to all shareholders of
      record.




**Item
      17** .
      Other
      Information





None.





**Item
      18. EXHIBITS AND REPORTS ON FORM 8-K**





**(a)**  **Reports
      on Form 8-K (See Item 3 for chronology of Company’s
      filings)**





**(b)**  **Exhibits**





Exhibits
      for the Company and its subsidiaries are listed below.





-
          33
          -




**INDEX
      TO EXHIBITS**





The
      exhibits designated by an asterisk (*) are filed herein. The exhibits not so
      designated are incorporated by reference to the indicated filing.





Exhibit
      No.  Description


2.1.1
            Agreement
                and Plan of Reorganization, dated May 12, 2006 (incorporated by reference
                from Exhibit 10.1 to a Form 8-K filed on May 16,
                2006)


3.1  Certificate
      of Incorporation (incorporated by reference from Exhibit 3.1 of Form SB-2 filed
      September 15, 1999)


3.2  Bylaws
      (incorporated by reference from Exhibit 3.1 to Form SB-2 filed September 15,
      1999)


3.3  Certificate
      of Designation for Series A Convertible Preferred Stock (incorporated by
      reference from Exhibit 10.1 to a Form 8-K filed on May 16, 2006)


31.1  Rule
      13a-14(a)/15d-14(a) Certification of Gilbert A. Kaats, Chairman ,Chief Executive
      Officer and Chief Financial Officer*


32.1  Section
      1350 Certification of Gilbert A. Kaats, Chairman, Chief Executive Officer and
      Chief Financial Officer*





*-Filed
      herewith








**SIGNATURES**





Pursuant
      to the requirements of the Securities Exchange Act of 1934, the registrant
      has
      duly caused this report to be signed on its behalf by the undersigned, thereunto
      duly authorized.





**SIGNATURE**
            
            **TITLE**
            
            **DATE**/s/
                Gilbert R. Kaats
            
            Chairman
                and CEO
            
            April
                16, 2007/s/
                Gilbert R. Kaats
            
            Chief
                Financial Officer
            
            April
                16, 2007





-
          34
          -